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NFAT1 CONTRIBUTES TO MELANOMA TUMOR GROWTH AND METASTASIS 
BY REGULATING IL-8 AND MMP-3 
 
 
Einav Shoshan, M.S. 
Supervisory Professor: Menashe Bar-Eli, Ph.D. 
 
Studies from our laboratory have recently demonstrated that Gal-3 regulates autotaxin 
through NFAT1 and support melanoma progression. These findings prompted us to further 
study the role of NFAT1 in melanoma progression and metastasis. NFAT1 is a transcription 
factor that was first identified in immune cells, acting as a positive regulator of interleukin-2 
by binding to its promoter during T cell activation. NFAT1 has an important role in the 
innate and adaptive immune response. In this dissertation I studied the mechanisms by which 
NFAT1 contributes to the acquisition of the melanoma metastatic phenotype. 
To identify the role of NFAT1 in melanoma progression we stably silenced NFAT1 
expression in the highly metastatic cell line, A375SM, and subjected the cells to gene 
expression microarray analysis. We identified and validated two downstream targets of 
NFAT1, i.e; IL-8 and MMP-3 to be downregulated following silencing NFAT1. While 
silencing of NFAT1 reduced IL-8 and MMP-3 in highly metastatic cell lines, A375SM and 
WM902B, overexpression of NFAT1 in the low metastatic cell line, SB2 induced the 
expression of both IL-8 and MMP-3.  We further demonstrated that silencing NFAT1 
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significantly reduced the promoter activity of IL-8 and MMP-3 and mutations of the NFAT1 
binding sites at either promoter reduced the promoter activity.  Rescue of NFAT1 increased 
both IL-8 and MMP-3 expression back to their initial levels, indicating that they are directed 
targets of NFAT1. Importantly, we demonstrated in melanoma patient specimens and cell 
lines that overexpression of NFAT1 is correlated with disease progression and 
staging.   Moreover, our in vivo studies demonstrated that NFAT1 is a major contributor of 
tumor growth and lung metastasis. The role of MMP-3 in melanoma progression has not 
been previously described. Therefore, we next decided to elucidate the role of MMP-3 in 
melanoma. Our in vivo studies demonstrated that MMP-3 contributes to melanoma tumor 
growth and metastasis. 
Collectively, our data assign a previously undescribed role for NFAT1in melanoma 
progression through the regulation of IL-8 and MMP-3. 
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Chapter 1: Introduction and Background 
 
Melanoma Occurrence 
Melanoma is considered to be the deadliest and most aggressive form of skin cancer.  
The annual death incidence of this disease is higher than any other skin cancer [1].  The 
current statistics are evidence that malignant melanoma presents a major clinical challenge 
due to limited treatment options.  In the United States, melanoma is documented as the fifth 
and seventh most common form of cancer in men and women respectively [2].  For 2014, 
there are 76,100 (43,890 in men, 32,210 in women) expected new cases of melanoma with 
9,710 of those cases resulting in death [2]. Although melanoma cases represent less than 5% 
of all skin cancers, it is responsible for more than 80% of deaths from skin cancer [3].  It 
seems that cutaneous melanoma is relevant for all major ethnic groups and races in the USA, 
however there are variations by race and ethnicity. In the USA non-hispanic white 
individuals are the most likely to develop melanoma in their life period [4].   To identify 
novel therapeutic molecular targets and successfully cure this disease, it is critical to 
understand the molecular events that lead to melanoma metastasis.  
 
Melanoma Development 
The onset of melanoma is largely due to a cohort of cellular, tissue, and/or 
environmental factors that lead to genetic and epigenetic alterations influencing the 
proliferation of normal melanocytes [5].  Melanocytes are cells of the skin that are 
responsible for producing the pigment melanin which in turn helps protect against the 
harmful effects of ultraviolet light.  Human melanocytes arise from neural crest (ectoderm) 
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cells that are only present during embryonic development and migrate in a coordinated 
fashion to be effectively incorporated into every follicle of hair and every unit of the human 
epidermis [6].  Over three decades ago, a study focused on the progression of tumor 
development led Clark et al. to propose that melanoma develops in a stepwise manner of five 
steps [7].  The first step to the model, Benign Nevus, involves the formation of a benign 
nevus due to an abnormal increase in proliferation of normal melanocytes.  In standard 
clinical observation, these nevi will appear as either flat or slightly raised lesions on the 
surface of the skin.  The pigmentation of these lesions can be either completely uniform or 
with a dot-like pattern [3].  In step two, Dysplastic Nevus, due to uncontrolled growth, the 
development of cytologic atypia arise from these newly formed benign nevi or in an entirely 
new location.  Clinically, these lesions lack uniformity, such that they are typically seen with 
irregularities in the borders and may contain multiple pigments [3].  Primary melanoma 
develops in the third stage termed the Radial Growth Phase (RGP).  In this step, cells now 
have the limited ability to only penetrate the epidermis and proliferate to form tumors [3].  
With progression of the tumor comes the ability of cells to fully invade the dermis to form 
lesions beyond the basement membrane. This is the fourth step and it is termed the Vertical 
Growth Phase (VGP).  At this step, cells gain the ability to form tumors when implanted in 
nude mice [3].  The fifth and final stage of the primary tumor is to form distant metastasis by 
dissociating from the primary tumor, entering the lymphatic system, and transporting into 
outlying organ sites to proliferate and form new tumors [3].  Among the most common sites 
for melanoma metastasis are bone, lung, liver and brain.  There is a second model for the 
development of melanoma that suggests that melanoma does not arise from molecular 
disturbances of a preexisting Dysplastic Nevus but rather as completely de novo [8].  The 
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transformation of melanocytes to melanoma is promoted through the activation of different 
cellular pathways that induce the genetic and epigenetic changes necessary for the 
development of melanoma [9].  Although both models are plausible for occurring in humans, 
the model that includes the five defined sequential steps is most widely accepted (Figure 1). 
 
Melanoma Staging and Survival 
Currently there are four distinct clinical classifications for melanoma.  The factors for 
prognosis are:  the thickness and presence or absence of ulceration of the primary tumor, the 
expression of lymph node metastasis, and the presence of distant metastatic disease [10].  
Those patients who are diagnosed within the first two stages have primary tumors with no 
identifiable metastasis.  Specifically, stage I melanoma is identified by the presence of 
primary tumors with a thickness of less than 2mm.  Furthermore, a sub-classification of stage 
I, stage IA and IB, distinguishes between tumors that are less than 1mm thick with no visible 
ulcerations (IA) and tumors that are also less than 1mm thick but are either ulcerated or have 
greater than one mitotic cell per mm
2
 (IB).  A tumor with thickness of up to 2mm with no 
ulceration (termed T2a melanoma) is also classified as stage IB [11].  Patients with stage II 
melanoma are sub-classified into either IIA or IIB depending on the tumor thickness which 
ranges from 1mm to greater than 4mm, and the presence or absence of ulcerations [10].  The 
stage of the disease is a critical factor in determining a patient’s prognosis, since the five year 
rate of survival in patients presenting an early stage of melanoma is 90% but those in stage 
IV of the disease (wide spread metastasis) only have a 10-20%  chance of survival [12-16].  
Crucial independent predictors for patient outcome and those that also contribute to the 
variation in survival are tumor thickness, mitotic rate, and presence of ulcerations [10, 17, 
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18].  Results from a 2011 study found a correlation between mitotic rate and the development 
of ulcerations and concluded that at ten years, there is a 33% chance of survival for patients 
with ulcerated tumors greater than 5mm as opposed to patients with ulcerations less than 
5mm in diameter who have a 69% chance of survival [17, 19].  At stage III melanoma, 
regional lymph node metastasis is present.  Three additional subcategories to stage III 
melanoma are IIIA, IIIB, and IIIC respectively.  The classification criteria depends on the 
number of regional lymph nodes present, the size of the lesion within the node (micro vs, 
macrometastasis), and if in transit metastasis is seen.  There is a 25-35% 10 year survival rate 
for patients with multiple affected lymph nodes (macrometastasis) opposed to 45-65% 
survival for patients with micrometastasis, one or two lymph nodes affected [11].  Stage IV 
melanoma involves patients with distant organ metastasis such as, but not limited, to the 
bones, brain, and lungs.  The ten year survival rate for patients in stage IV melanoma is less 
than 20% [11]. Recently it was published that age is a prognostic factor in melanoma patients 
and it can also be used as a predictor of sentinel node metastasis [20, 21]. These reports show 
that older patients with stage I and II had lower survival rates and higher incidence of nodal 
metastasis. 
Current Treatments for Metastatic Melanoma 
Historically, systemic therapy for metastatic melanoma was in the form of a DNA 
damaging compound named decarbazine (DTIC) and it was approved by the FDA in 1975 
[22].  The response rate for the alkylating agent DTIC is low, only 5-12%, with long term 
response in less than 2% of patients [23], it remains as the standard treatment for many years 
while new therapies were tested [24].  An oral analogue to decarbazine is temozolemide, 
another alkylating agent that has a broad spectrum of anti-tumor effect and is much less toxic 
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than decarbazine [25].  Currently, temozolemide is routinely utilized in place of decarbazine 
for therapeutic purposes [24]. The first nonspecific immunotherapeutic drug approved before 
2011 for the treatment of malignant melanoma was a high dose of Interleukin-2 (IL-2), but it 
demonstrated only a 15% response rate, and it remains nonspecific whereby treatment 
requires high dosages leading to intolerability and other side effects [26].   Adjuvant therapy 
is the term for a treatment that is given after surgical removal of the melanoma tumor. The 
cytokine, Interferon-alpha (IFN-α) was approved for use as adjuvant therapy for patients with 
early stage melanoma in order to reduce the risk for disease progression.  After primary 
tumors are resected, and when there is no involvement of the lymph nodes, patients can be 
treated with high or low doses of IFN-α [27]. Furthermore, because of the significant dose-
dependent side effects linked to adjuvant therapies, careful consideration must be taken when 
deciding whether or not to undergo such treatment. 
 Within the past years, rigorous research studies focused on understanding the 
complex interaction between tumors and their microenvironment have led to the 
development of some newly FDA approved anti-tumor drugs with increased immune 
specificity [24]. Ipilimumab, a safer T-cell activating agent, is the first among the four most 
recent drugs approved by the FDA.  In 2011, ipilimumab was approved as a therapy for 
advanced melanoma.  Ipilimumab is a monoclonal antibody against cytotoxic T lymphocyte 
associated antigen 4 (CTLA-4). CTLA-4 is responsible for inhibiting T cells to prevent 
autoimmune response. Ipilimumab allowed stronger T cell activation against malignant 
melanocytes, allowing prolonged immune responses to tumor antigens by preventing the 
down regulation of T-cell activation [28].  A clinical study performed on cases of stage IIIC 
and IV melanoma with no previous treatment found that the overall two year survival rate 
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increased by 10% when patients were treated with a combination of ipilimumab and DTIC as 
compared to DTIC alone [29].  In the clinical setting, the FDA recommends the ipilimumab 
regimen to consist of a concentration of 3 mg/kg per dose administered 3 weeks apart in 4 
cycles [30].  However, a number of auto-immune related adverse effects including adrenal 
insufficiency, rash, diarrhea/colitis, and hypothyroidism appear in patients several weeks 
after being treated with ipilimumab [31].   Programmed cell death protein 1 (PD-1) is a 
protein expressed on T cells and plays a role in tumor cells escaping the immune response. 
When PD-1 interacts with the ligand PD-L1, it inhibits T cell proliferation and induces 
apoptosis of T cells [32]. In recent years it was demonstrated that PD-1/PD-L1 plays a role in 
immunosuppression of tumor cells. Using antibodies against PD-1 exhibited good results in a 
phase 1 clinical trial that included melanoma [33]. Only patients expressing the PD-L1 ligand 
on tumor cells were found to be suitable for the trial.  Anti PD-1 and anti-PD-L1 are still 
being tested [33].  
The other FDA approved drugs within the last years are therapies designed to target 
gene mutations of the RAS/RAF/MEK/ERK pathway.  Since the most mutated protein in 
cancer is BRAF, the development of vemurafenib was pivotal as a potent and specific BRAF 
inhibitor [34, 35].  Currently, 40-60% of metastatic melanomas contain BRAF mutations, 
where a substitution for valine at the 600th amino acid position (V600E) is the most 
common, BRAF
V600E
 mutation. To analyze vemurafenib response rate, a randomized phase 3 
clinical trial that included 675 patients with stage IIIC or IV melanoma that also was both 
untreated and resectable demonstrated that after treatment with an oral dosage of 960 mg 
twice daily, a decrease of ~50% in tumor size was demonstrated  with an improvement in 
progression free survival of ~5 months and an overall 6 month survival of ~85% 
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[36].  Resistance to vemurafenib is typically seen in all patients.  Either the activation of 
alternative pathways or the reactivation of the mitogen-activated protein kinase creates this 
resistance thereby creating a need for combination treatments that include downstream and 
alternative pathway blocking agents [37, 38].  Current insights propose that a more effective 
therapeutic approach involves the use of individual inhibitors to simultaneously target RAF 
and MEK rather than targeting either kinase alone [39-41].  Dabrafenib was approved in May 
2013 for the treatment of metastatic melanoma.  This agent actively works against 
BRAF
V600E 
mutations and when compared to decarbazine, established a 3 months increase of 
the progression free survival rate.  Interestingly, even though dabrafenib has a reduced blood 
brain barrier capability, a phase 2 study with cases involving brain metastasis with tumors 
harboring the V600E mutation had an overall intracranial response rate of ~40% (previously 
untreated cases) and ~30% (previously treated cases) when administering a dosage of 150 mg 
dabrafenib 2 times a day [42]. Trametinib is a pharmacological MEK inhibitor that was 
approved in May 2013 by the FDA, for melanoma patients with BRAF
V600E
 mutations. 
Patients treated with trametinib showed an increase of ~3 months progression free survival 
compared to chemotherapy alone [43]. Two notable combination therapies are 
dabrafenib/trametinib and vemurafenib/cobimetinib.  In January 2014 the combination drug 
dabrafenib/trametinib was FDA approved for use in treating metastatic melanoma cases with 
unresectable tumors or containing BRAF
V600E/V600K
 mutations [44].  The response rate was 
~75% with response duration of ~10 months compared to treatment with dabrafenib alone 
which yielded a ~55% response rate with ~ 5 month response duration [24].  Another 
promising therapy is the combination of vemurafenib/with the MEK inhibitor, 
cobimetinib.  Although FDA approval is yet to be obtained, findings from early data suggest 
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that this combination therapy significantly improves clinical outcomes in patients with 
advanced BRAF
 V600 
mutated metastatic melanoma [45].  The rate of response is increased in 
more than 20% in the combination group compared to the control group.  Furthermore, an 
increase of ~10% in overall survival rate is observed in the combination group [45]. 
Genetic Alterations during Melanoma Progression 
A wide array of both genetic and epigenetic events takes place throughout the 
progression of melanoma which leads to the initial formation of cutaneous melanoma and 
eventually metastasis.  There are several genes whose genetic changes play a fundamental 
role in transitioning the initial stage of melanoma (benign nevi) to premalignant lesions. 
Some of these important genes includes:  NRAS, cyclin D1, PTEN, BRAF, and CDKN2A.   
BRAF is an oncogene that when mutated has the potential to cause normal cells to 
become cancerous.  As a member of the RAF family, BRAF acts on the map kinase 
(MAPK), RAS/RAF/MEK/ERK signaling pathway [46].  An amino acid substitution at 
position 600 from a valine (V) to a glutamic acid (E) in BRAF results in the V600E mutation.  
The V600E mutation in BRAF along with NRAS, the upstream molecule that activates 
BRAF, are indicators of the critical role that the MAPK pathway plays in melanoma 
progression.  While the V600E mutation is seen in approximately 40-60% of melanoma 
cases, only 20-30% of the upstream NRAS mutations are present [47-50]. These two 
mutations are mutually exclusive in melanoma.  Contradictive to the records that suggest 
BRAF
V600E
 is essential for melanoma progression is a study that has shown that although 
80% of melanocytic nevi contain BRAF mutations, not all progress into primary melanomas 
[51] and that the introduction of BRAF
V600E 
in melanocytes can induce cell senescence and 
apoptosis [52]. An explanation for this event comes from the presence of other molecules, 
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such as the tumor suppressor gene cyclin dependent kinase inhibitor 2A (CDKN2A) which 
inhibits BRAF
V600E 
and therefore prevents BRAF from releasing cells from senescence and 
inducing cell growth.  CDKN2A is important in melanoma progression since (through 
alternative mRNA splicing) this gene encodes p16
Ink4A
, a known inhibitor of cyclin D/CDK4 
complex, and p14
ARF
, an inhibitor of MDM2, which regulates p53 [46, 53, 54].  The 
proliferating effects of BRAF
V600E
 are restricted since an increase of p16
Ink4A
 expression is 
observed in melanocytic nevi in comparison to normal dermis [55].  Primary melanomas 
have a 7% incidence of mutations in the p16
Ink4A
 gene while it is present in 14% of metastatic 
lesions [56].  Mutation in the CDKN2A gene is often linked to patients with melanoma in 
their family history or UV exposure/damage.  There are other genetic events that could adopt 
NRAS and BRAF mutations, which influence a greater chance of developing the disease [57, 
58].   
The loss of PTEN is also an important determinant in melanoma development.  The 
action of PTEN is that of a phosphatase which removes phosphates from phosphatidylinositol 
phosphate (PIP3) which then behaves like an intracellular signal catalyzed by growth factors 
or other stimuli [3, 59].  PIP3 recruits the protein phosphoinositide-dependent kinase 1 
(PDK1). Then, PDK1 phosphorylates AKT, which acts as a survival factor [60].  The 
phosphatase PTEN dephosphorylates PIP3 (PtdIns (3,4,5)) on the 3 position, generating PIP2 
(PtdIns (4,5)) and causes inactivation of the AKT signaling cascade [59].  Early studies 
indicated that the deletion on chromosome 10q occurs in melanoma in 30-50% of melanomas 
[61, 62], and later this deletion was connected with the location of the tumor suppressor 
PTEN which is located within the long arm of chromosome 10, specifically chromosome 
band 10q23.3 [63, 64].  It was discovered that 60% of melanoma cell lines carry hemizygous 
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deletions of chromosome 10q [64] and 10% can be observed in primary melanomas [65, 66].  
Immunohistochemistry studies revealed that almost all melanomas without PTEN expression 
showed no deletion or mutation suggesting that the loss of expression can also be a result of 
transcriptional repression or epigenetic regulation [67].  PTEN loss-mediated AKT activation 
promotes cell survival and proliferation in melanoma [68].  In the step involving the 
transition from dysplastic nevus to primary melanoma, the phosphorylation of AKT is 
increased and multiple processes are affected [68]. One example is the increased interactions 
between AKT and N-cadherin which leads to inactivation of BAD the pro-apoptotic protein. 
This interaction promotes melanoma cell survival [69]. AKT activation in melanoma is also 
associated with the upregulation of NFkB. AKT phosphorylates the protein IKKβ inducing 
its activity and then IKKb phosphorylates IKβ which is an inhibitor of NFκB. In that way, 
removing IKβ inhibition allows for NF-kB to be actively transcript.  NFκB is responsible for 
the transcription of angiogenic and pro-tumorogenic genes as VEGF, Cox-2, Bcl-2, MMPs 
and IL-8 among others [70, 71].  
In the last two decades our lab is investigating the molecular and cellular changes that 
occur during the shift from RGP to VGP in melanoma progression. The transcription factor 
activator protein 2 alpha (AP2α) is lost during this transition [72-74].  This is a specific 
characteristic of the melanoma phenotype since less metastatic melanoma cells have higher 
AP2α expression when compared to highly metastatic cell lines [75].  AP2α is 52 kD and is 
regulated by cyclic AMP (c-AMP) and retinoic acid (Vitamin A) [76-78]. AP2α expression is 
inversely correlated with genes like the protease activated G-protein coupled receptor (PAR-
1) and the membrane adhesion molecule MCAM/MUC18 that are known to be pro 
tumorogenic [75, 79].  As a mode of action, AP2α will bind to the promoters of both 
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MCAM/MUC18 and PAR-1 to suppress their transcriptional activity [72-75, 79].  Loss of 
expression of nuclear AP2α is connected to melanoma progression through an observable 
increase in MCAM/MUC18 and PAR-1.  MCAM/MUC18 is a cell adhesion molecule, and 
silencing it leads to a reduction in melanoma tumor growth and metastasis [80].  
 PAR-1 is another important molecule that plays a role in melanoma progression. It is 
an inflammatory molecule known to be upregulated during the RGP to VGP transition.  
PAR-1 promotes normal platelet aggregation through its cleavage in the extracellular domain 
by thrombin.  In melanoma, PAR-1 enhances vascular endothelial growth factor (VEGF) and 
matrix metalloproteinase-2 (MMP2) expression in the microenvironment, thus supporting 
tumor growth and metastasis. PAR-1 increases the expression of Connexin-43, another pro 
tumorogenic gene and suppresses maspin, a known tumor suppressor gene [81-83].  
Silencing of PAR-1 has shown reduction in melanoma growth and metastasis via Connexin-
43 [82].  
c-AMP response element binding protein (CREB) is another transcription factor that 
significantly overexpressed during the transition from RGP to VGP. Previous reports from 
our laboratory have shown that CREB serves many important functions during this transition 
[84, 85], including acting as a survival factor and increasing cell invasion by regulating 
MMP2, IL8, BCL2, MCAM/MUC18, and the tumor suppressor CYR61 [86-89]. 
Furthermore, CREB regulates other important transcription factors involved in melanoma 
progression such as, MITF and AP2α [90, 91]. To further evaluate CREB’s role during 
melanoma progression, recently we performed gene expression profiling in metastatic 
melanoma cells following CREB silencing and identified an important and previously 
unknown target for CREB, the RNA-editing enzyme adenosine deaminase acting on RNA 1 
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(ADAR1).   The activation of CREB plays an important role in regulating genes that are 
important for inflammation, invasion, and survival [87, 92, 93].  CREB is activated through 
phosphorylation at Ser133 and binding to the co-activators CBP and p300 [94, 95].  During 
melanoma progression, the activation of CREB can both induce the expression of various 
pro-tumerogenic genes including MCAM/MUC18 and MMP2 [87] as well as inhibit the 
expression of other genes, like CYR61.  CYR61 has been shown to be a regulator of cell 
proliferation, survival, migration, and extracellular matrix formation [96]. Upon silencing 
CREB, CYR61 expression is increased and motility and invasion reduced in vitro. Silencing 
CREB reduced tumor growth and metastasis in melanoma in vivo [89].  Melanoma cells 
become susceptible to apoptosis when a dominant negative form of CREB is overexpressed 
[86].  Silencing CREB increases p21
waf1
, a cell cycle inhibitor, while an increase in CREB 
activity directly suppresses AP2α expression during melanoma progression.  Since AP2α is a 
positive regulator of p21
waf1
, CREB has a significant effect on melanoma cells through its 
regulation of other transcription factors that in turn regulate different genes [91].  Past and 
latest findings emphasize the importance of CREB in melanoma growth and metastasis as the 
“master switch” in melanoma progression. 
Activating transcription factor -2 (ATF-2) which belongs to the CREB family, also 
has been shown to have a role in melanoma progression [97, 98]. When ATF-2 is activated it 
promotes melanoma progression and cell growth by inducing such genes as c-Jun and TGFβ. 
Silencing ATF-2 reduced tumor growth and metastatic potential of melanoma cells [98, 99]. 
Many other important transcription factors are being deregulated during melanoma 
progression. SNAIL and SLUG transcription factors are known to inhibit transcription of E-
cadherin [100]. Silencing SLUG increased melanoma susceptibility to chemotherapeutics as 
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cisplastim [101] . The TWIST transcription factor is known to be a metastasis regulator in 
epithelial cancers responsible for epithelial-to-mesenchymal transitions (EMT). However, in 
melanoma its role is unclear due to the ambiguous role of EMT in melanoma invasiveness 
and metastasis [102]. Inspite all these new modalities, further research is needed to 
understand the biology since BRAF resistance and the fact that only 30-40% response to 
immunecheckpoint therapies. All these genetic alterations mentioned and many other 
molecular classifications in melanoma progression are very important for planning new 
targeted therapies. Another molecule contributing to melanoma growth and metastasis is 
Galactin-3 (Gal-3). Our studies identified Gal-3 as the major regulator of autotaxin and 
NFAT1. This thesis will concentrate on the transcription factor, NFAT1 and further 
investigate the contribution of NFAT1 to the metastatic melanoma phenotype.  
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Figure 1:  Molecular and Genetic Changes During Melanoma Progression  
The progression of melanoma is a stepwise process. From benign nevus to dysplastic nevus genetic 
mutations occur within the BRAF or NRAS genes.  The loss of PTEN or p16
INK4A/ARF
 expression are 
early events in a subset of melanomas.  The tumor then grows radially throughout the epidermis 
termed the radial growth phase.  The acquisition of multiple factors such as CREB and NFB 
activation as well as enhanced expression of MCAM/MUC18, PAR1, Il-8, MMP-2 and galectin-3 
induce the degradation of the basement membrane and invasion of melanoma cells termed the vertical 
growth phase (VGP).  Finally, a few select melanoma cells intravasate, circulate, and survive in 
distant organ sites where metastasis forms. This figure reproduced with permission from (Miller AJ 
and Mihm MC Jr., N Engl J Med 2006 [3]), Copyright Massachusetts Medical Society, and 
Melnikova et al. Cancer Biol Ther 2008 [87]. 
  
15 
 
Nuclear Factor of Activated T cell – NFAT Transcription Factor 
Nuclear Factor of Activated T cell (NFAT) proteins were first identified in T cells as 
activators of the transcription of interleukin 2 [103, 104], which serve as a key regulator of T 
cell immune response. NFAT family members are transcription factors that play an important 
role in inducing the transcription of central genes during the immune response. All family 
members have a highly conserved REL-homology domain (RHD), which is a DNA binding 
domain.  They are also involved in the control of T cell development and T cell 
differentiation [105]. Many years after the discovery of the NFAT gene family, they were 
found to play many roles in other biological systems besides the immune response. Despite 
their name, proteins from the NFAT family are expressed also on other cells and not only on 
T cells.  
Calcium flux, calcineurin and NFAT kinases are the regulators of NFAT family.  Calcium 
that is released from intracellular stores increases the levels of intracellular calcium. Calcium 
binds to calmodulin which then activates the calcineurin phosphatase. In order to be active, 
NFAT proteins are regulated by calcineurin, a phosphatase that dephosphorylates NFAT 
proteins to uncover their nuclear localization site (NLS), thus triggering their mobilization 
from the cytoplasm to the nucleus. In the nucleus, NFAT proteins cooperate with other 
factors to regulate gene expression for various biological functions [105].   The phosphatase 
calcineurin responds to a continued rise (not transient) of calcium in the cytoplasm, therefore 
NFAT is dephosphorylated and imported into the nucleus for the duration of the transcription 
[106]. In order to dephosphorylate NFAT, calcineurin needs to stably dock on NFAT, usually 
on a region located on the protein N-terminal. Furthermore, the weak DNA binding of NFAT 
requires that NFAT partner with other factors to perform transcription regulation. Such 
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partners can be MEF to control muscle development, GATA in heart development, FOXP3 
to regulate immune tolerance and AP-1 to activate T cell response [107, 108].  
The NFAT family of proteins contains five family members, NFAT1-NFAT5, that 
are all evolutionarily related to the Rel family.  There are four typical members in the NFAT 
family (NFAT1-4) that indeed are regulated by calcinurin, in difference to these; NFAT5 
does not require calcineurin or a nuclear partner for its activity.  The NFAT protein family 
(NFAT1-4) has few functional modules sites on the protein: phosphorylation sites, nuclear 
localization site, DNA binding site, and transactivation sites (Figure 2).  The N-terminal 
region includes regulatory domains like, casein kinase 1 (CK1), calcineurin (Cn) docking 
sites, and transactivation domain (TAD). The C-terminus includes the nuclear localization 
site (NLS), DNA-binding Rel homology domain (RHD) and an additional calcineurin 
docking site. In the middle of the protein there are several serine rich domains (SP1-3) that 
provide phosphorylation sites for kinases targeting NFAT. Furthermore, the NFAT protein 
contains two signal sequences that regulate its subcellular localization: the nuclear 
localization signal sequences (NLS1 and NLS2) and the nuclear export signal (NES) (Figure 
2).  When NFAT proteins are phosphorylated on their serine residues, they are localized in 
the cytoplasm [108]. The activation of receptors on the cell surface for example: receptor 
tyrosine kinases (RTKs), T cell receptor (TCR), receptors, and G protein coupled receptors 
(GPCRs), lead to a signaling cascade that starts causing calcium influx into the cytoplasm. 
When this influx is sustained, it causes the activation of calcineurin, which then 
dephosphorylates the cytoplasmic NFAT proteins. Dephosphorylation of NFAT by 
calcineurin exposes the nuclear localization site (NLS), causing the protein to transfer into 
the nucleus [109].  Calcineurin can be inhibited by the immunosuppressant cyclosporine A 
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(CsA) and tacrolimus (FK506), which form binding protein complexes which bind and 
competitively inhibit calcineurin phosphatase activity [110].  To neutralize NFAT activation, 
it needs to be rephosphorilated and mobilized outside the nucleus. Several kinases act to 
phosphorylate NFAT proteins, for example: protein kinase A (PKA), casein kinase 1 (CK1) 
and more. In the immune system the NFAT family of proteins is well established and their 
role in activating T cells is clear. There is an established clinical knowledge of NFAT being 
active in the regulation of T cells and in organ rejection after transplantation.  Inhibitors like 
CsA and FK506 help in preventing this rejection. However the functions of the NFAT family 
of proteins in other aspects of human diseases and cancer are largely unknown. 
In recent years there is more and more evidence that the NFAT family members are 
also involved in cancer development and metastasis. Phenotypes such as increase cell 
growth, enhanced proliferation, stimulates angiogenesis and increased resistance were 
reported in the literature about the NFAT family [111].  In our research we have been 
concentrating on one NFAT family member the NFAT1.   Here in I will test the hypothesis 
that NFAT1 is not solely involved in T cell activation but could also regulate the melanoma 
metastatic phenotype.  
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Figure 2: Primary Structure of NFAT 
Schematic structure of NFAT. The region of highest homology within NFAT proteins is the DNA-
binding Domain, Rel homology domain (RHD), which shows similarity to the Rel homology region 
of Rel-family transcription factors. A second region of homology is the NFAT homology region 
(NHR), which contains all regulatory domains. The N-terminal region includes regulatory domains 
like, casein kinase 1 (CK1), calcineurin (Cn) docking sites, and transactivation domain (TAD). The 
C-terminus includes the nuclear localization site (NLS), DNA-binding Rel homology domain (RHD) 
and an additional calcineurin docking site. In the middle of the protein there are several serine rich 
domains (SP1-3) that provide phosphorylation sites for kinases targeting NFAT. Furthermore, the 
NFAT protein contains two signal sequences that regulate its subcellular localization: the nuclear 
localization signal sequences (NLS1 and NLS2) and the nuclear export signal (NES).   
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Nuclear Factor of Activated T Cell 1 – NFAT1  
NFAT1, also known as NFATc2, is the first member of the NFAT family that was 
discovered on T cells. NFAT1 is a transcription factor bound to the antigen receptor response 
element on the interleukin-2 (IL-2) promoter. NFAT1 family member is expressed on T 
lymphocytes but also on many other cells outside the immune system. In equilibrium, 
NFAT1 is greatly phosphorylated and its activation can be reached through 
dephosphorylation by calcinurin phosphatase [105]. Similar to the other family members, 
NFAT1 activation can be blocked using calcineurin inhibitors like tacrolimus (FK506) or 
cyclosporine (CsA) [110]. The dephosphorylation of NFAT1 helps the protein to be relocated 
into the nucleus and to be active as a transcription factor, as previously described. In recent 
years there is more and more evidence that NFAT1 is associated with cancer. 
NFAT1 in Cancer 
NFAT1 was published to be associated with cancer; it was showen to be associated 
with a wide range of tumor progression events such as: invasion, migration, tumor cell 
survival, and apoptosis.  In breast cancer, high expression of NFAT1 was found in patients’ 
specimens with primary tumors or lymph node metastasis, when compared to healthy tissue 
[112]. It was also found that there is a negative cross talk between NFAT1 and Stat5 
signaling cascades [112]. These results highlight the effect of NFAT1 on breast tumor 
formation and metastasis.  Primarily in breast cancer, it was demonstrated that NFAT1 
enhances cell invasion and cell motility by regulating a variety of downstream genes [113]. 
One of the mechanisms by which NFAT1 to promote cell invasion in breast cancer was 
found to be through the induction of Cyclooxygenase-2 (COX-2), which is responsible for 
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the production of prostaglandins [114]. In 111 clinical samples of glioblastoma, NFAT1 was 
overexpressed compared with lower grade gliomas. NFAT-1 expression in glioblastoma cell 
lines was correlated with higher invasion and with the expression of genes which enhance 
invasion such as: MMP-7, MMP-9 and COX-2 [115]. In the melanoma literature there are 
few works done on NFAT1. NFAT1 deficient mice (NFAT1-/-) presented less experimental 
lung metastasis growth after melanoma cell injections when compared to the WT mice [116]. 
The absence of NFAT1 expression in the microenvironment causes a significant difference in 
the ability of the B16F10 melanoma cell line to progress [116].  Further research presents 
NFAT1 as a potential therapeutic target in melanoma, since NFAT1 was found to inhibit 
melanoma cell apoptosis and promoting proliferation [117]. NFAT1 was found to be an 
activating transcription factor for the MDM2 oncogene and as a response to DNA damage 
signals, NFAT1-MDM2 pathway is activated to inhibit p-53 function [118]. NFAT1 was 
demonstrated to support tumor-induced anergy of CD4
+
  T cells [119] as well as regulate a 
set of genes that are responsible for helper T-cell (CD8
+
) anergy [120]. A recent paper 
demonstrated that NFAT1 increased CTLA-4 promoter activity at CD4
+
 T cells compared to 
CD8
+
 T cells. This preferential expression of CTLA-4 on CD4, which is mediated by 
NFAT1, can be important for the anti CTLA-4 therapy [121]. All these data clearly indicate 
that NFAT1 is a regulator of multiple genes during cancer progression. Yet in melanoma the 
majority of the downstream genes are still not identified and the effect of NFAT1 on 
melanoma metastatic phenotype still needs to be elucidated.  Our laboratory has previously 
demonstrated that Gal-3 contributes to melanoma growth and metastasis via the regulation of 
autotaxin and NFAT1 [122]. In this present thesis I will expand on these results and identify 
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other targets genes, besides autotaxin, that are regulated by NFAT1 and contributing to 
melanoma growth and metastasis (see specific aims). 
 
 
 
 
 
 
 
 
 
Figure 3: Calcium Signaling and Activation of NFAT1  
Activation of the T-cell receptor (TCR) triggers the activation of receptor-associated tyrosine kinases 
that lead to the activation of phospholipase C-  (PLC- ). Activated PLC-  causes the hydrolysis of 
phosphatidylinositol-4,5-bisphosphate (PIP2), which generates inositol-1,4,5-trisphosphate (IP3) and 
diacylglycerol (DAG). IP3 binds to its receptor and induces an increase in intracellular calcium levels 
that is caused by the depletion of intracellular stores. This increase triggers the opening of calcium-
release-activated calcium channels (CRAC) in the plasma membrane, which leads to a sustained 
increase in intracellular calcium levels. Calcium binds calmodulin(CM) and activates calcineurin 
(Cn). Activated calcineurin dephosphorylates nuclear factor of activated T cells (NFAT1) proteins, 
which exposes their nuclear-localization signal (NLS) and induces their nuclear translocation. After it 
has entered the nucleus, NFAT1 interacts with activator protein 1 (AP1) and other transcriptional 
partners to promote gene transcription. The activation of these partners during T-cell stimulation 
might be elicited by signals that are transmitted through different signalling pathways. The activity of 
NFAT1 is also regulated by kinases, such as casein kinase 1 (CK1) and glycogen-synthase kinase 3 
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(GSK3), which help to maintain NFAT1 in a phosphorylated state in the cytosol (maintenance 
kinases) or induce the rephosphorylation of nuclear NFAT1 to expose a nuclear-export signal (NES) 
and translocate NFAT1 back to the cytosol (export kinases).  
Specific Aims 
 
NFAT1 was historically identified as inducible transcription factor in T cells [103]. In 
melanoma it was shown that NFAT1 expression in the microenvironment increases the 
invasive and metastatic phenotype of B16F10 murine melanoma cells [116]. We have 
previously shown in our lab that Galactin-3 is regulating autotaxin through NFAT1 in 
melanoma [122]. It is possible that in melanoma there are additional novel genes that could 
be regulated by NFAT1 to support melanoma growth and metastasis. Therefore we 
hypothesized that in addition to its role in the immune system, and to autotaxin 
regulation in melanoma, NFAT1 regulates the expression of additional downstream 
targets that contribute to the metastatic melanoma phenotype. 
 
To test this hypothesis we developed the following specific aims:   
 
Specific Aim 1:  To Determine the Status and Contribution of NFAT1 to Melanoma 
Progression  
1.1 Examine the Status of NFAT1 in Melanoma Progression 
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1.2 Study the In Vitro and In Vivo Effects of Silencing NFAT1 in Metastatic Melanoma 
Cell Lines and the Effects of Overexpression NFAT1 in Low Metastatic Cell Lines 
 
Specific Aim 2: To Identify Novel NFAT1 Downstream Target Genes that Contribute to 
the Metastatic Melanoma Phenotype 
2.1 Study NFAT1 as a Potential Regulator of IL-8 Expression in Melanoma Cells  
2.2 Study NFAT1 as a Potential Regulator of MMP-3 Expression in Melanoma Cells  
2.3 Determine the Contribution of MMP-3 to Melanoma Growth and Metastasis 
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CHAPTER 2:  Materials and Methods 
 
Cell lines and Cell Culture  
Human A375SM cells were collected from nude mice that were i.v injected A375P (parental) 
cells, pooled lung metastasis and grown in culture as described previously [123].  The human 
SB2 melanoma cell line was isolated from a primary cutaneous lesion and is non-metastatic 
and poorly tumorigenic in mice [124].  WM902B cell line was isolated from skin malignant 
melanoma in the vertical growth phase (VGF). All cell lines were cultured in Eagles 
minimum essential media (MEM) supplemented with 10% fetal bovine serum (FBS), and 1% 
of HEPES buffer, penicillin-streptomycin, sodium pyruvate and nonessential amino acids, 
and kept at 37°C in a 5% CO2 incubator.  The human embryonic kidney cells (293FT) were 
used for lentiviral shRNA and overexpression vectors were maintained in DMEM 
supplemented with 10% FBS.  Sixteen hours before each in vivo injection experiment, cells 
were replenished with fresh 10% FBS MEM.  Cell lines in exponential growth phase were 
harvested by 2-5 minutes exposure to 0.25% trypsin-0.02% EDTA solution. The cells 
removed from flasks were pipetted to generate a single-cell suspension. The cells were 
resuspended in PBS to the desired cell concentration just before the injecions. Cell viability 
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was determined by trypan blue exclusion and only single-cell suspensions with more than 
95% viability were used for in vivo injections.  
 
 
 
Lentiviral shRNA  
NFAT1 targeting shRNA 5’- CTGATGAGCGGATCCTTAA -3’ or MMP-3 targeting 
shRNA 5’-TCTGAACAAGGTTCATGCT-3’ and Non Targeting (NT) shRNA 5’-
TTCTCCGAACGTGTCACGT-3’ were designed with a hairpin and inserted into a pSIH-HI-
copGFP lentiviral vector.  The lentivirus was then produced by transfecting 293FT cells with 
the pSIH vector containing either the NFAT1/MMP-3 or NT shRNA sequence, the 
packaging plasmid (MD2G), and the envelop plasmid (PAX2) to produce a viable virus.  The 
NT shRNA has no homology to any known human genes.  The supernatant was collected 
containing a mature virus and was concentrated 10 times.  A375SM and WM902B cells were 
plated at 70% confluence on a six well plate and were transduced with 800ul MEM / 200ul of 
supernatant containing the virus and were incubated overnight.  The cells were then grown in 
culture and the top 50% GFP expressing cells were cell sorted by FACS.   
 
Nontargetable NFAT1 Expression Vector, Empty Vector (EV) 
  
26 
 
The NFAT1 gene (Isoform D) was amplified from A375SM cDNA with the following 
primers; Forward 5’- 
ATAAGAATGCGGCCGCGCCACCATGCAGAGAGAGGCTGCGTT 
CAG-3’ and Reverse 5’- GCTCTAGATAATATGTTTTGTATCCAGCTAAG-3’, cut with 
NotI and XbaI restriction enzymes, and inserted into the pCDNA3.1(+) vector.  The NFAT1 
shRNA targeting site was mutated to CAGACGAACGCATACTAAA (the underlined 
nucleotide are the entitled mutated sites) with the following primers; nfat1-Forward 5’- 
CTTCAGATCTT CATTGGGACAGCAGACGAACGCATACTAAAGCCGCA 
CGCCTTCTACCAGG-3’  and  Reverse- 5’-CCTGGTAGAAGGCGTGCGGCTTTAGTAT 
GCGTTCGTCTGCTGTCCCAATGAAGATCTGAAG-3’. This construct was used as a 
control for both NFAT1 rescue in highly metastatic A375SM and WM902B cells and 
NFAT1 overexpression in the low metastatic SB2 cells throughout the work. 
 
NFAT1 overexpression Lentiviral Vector   
NFAT1 gene (Isoform D) was cloned fromA375 cDNA into pCDNA3.1(+), using the 
following primers NFAT1XbaIF-5’-GCTCTAGAGCCACCATGCAGAGA-
GAGGCTGCGTTCAG-3’ and NFAT1NotIR-5’- 
ATAAGAATGCGGCCGCTCATAATATGTTTTGTATCCAG-3’. NFAT1 gene was cut 
with the designated restriction enzymes, inserted into a pCDH-CMV-MCS-EF1-puro vector 
and packaged with MD2G and PAX2 plasmids in a lentiviral virus as previously described. 
SB2 cell line was plated at 70% confluence on a six well plate and then transduced with 
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800ul MEM / 200ul supernatant containing virus overnight and were selected with MEM 
containing 1ug/ml puromycin. 
 
NFAT1 Rescue Lentiviral Vector   
NFAT1 rescue gene was generated on NFAT1-pCDNA3.1(+), using the following primers 
NFAT1-res-F-   5’-CTTCAGATCTTCATTGGGACAGCAGACGAACGCATACTA 
AAGCCGCACGCCTTCTACCAGG-3’ and NFAT1-res-R- 5’-CCTGGTAGAAGGCGTGC 
GGCTTTAGTATGCGTTCGTCTGCTGTCCCAATGAAGATCTGAAG-3’. NFAT1 rescue 
gene was cut with the designated restriction enzymes, inserted into a pCDH-CMV-MCS-
EF1-puro vector and packaged with MD2G and PAX2 plasmids in a lentiviral virus as 
previously described. A375SM and WM902B cell lines which NFAT1 was silenced using 
NFAT1 shRNA  lentiviral vector were plated at 70% confluence on a six well plate and then 
transduced with 800ul MEM / 200ul supernatant containing virus overnight and were 
selected with MEM containing 1ug/ml puromycin. 
 
MMP-3 Overexpression Lentiviral Vector  and Nontargetable MMP-3 vector -EV 
MMP-3 gene overexpression plasmid was purchased from shRNA and ORFeome core 
facility at MD Anderson. The gene was inserted into a PLOC vector which has RFP and 
Blasticidin as markers and packaged in a lentiviral virus as previously described. 
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Nontargetable MMP-3 expression vector (EV) was purchased from shRNA and ORFeome 
core facility at MD Anderson as well.  SB2 cell line was plated at 70% confluence on a six 
well plate and then transduced with 800ul MEM / 200ul supernatant containing virus 
overnight and were selected with MEM containing 1ug/ml puromycin. 
 
Fluorescence activated cell sorter and flow cytometry (FACS) 
A375SM, WM902B and SB2 cells which were transduced with lentiviral constructs were 
detached from the flask using Tripsin EDTA 0.05%. Cells were centrifuged at 1400 rpm and 
the supernatant was removed. Cells were than resuspended in 500ul of PBS and were obtain 
into FACS.  
 
Protein extraction 
Total protein extracts were acquired from 70%-80% confluent cell culture on a six well plate 
or 10 cm dish.  Cells were washed twice with cold PBS. After complete drain of PBS cells 
were incubated 10 min on ice with 200ul of RIPA “B” lysis buffer (1% Triton x-100, 150mM 
NaCl, 5mM EDTA, 20mM Sodium Phosphate, pH-7.4)  supplemented with 1% protease 
inhibitor cocktail (Roche). Cells were scraped from the plate using a scraper and lysates were 
transferred into a 1.5ml clean tube. After 30sec of vortexing, lysets were centrifuged at 
14,000 rpm at 4
o
C for 15 min and supernatant was collected. Protein concentration was 
measured using Bradford assay (Bio-Rad). 
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Western Blot Analysis 
To detect NFAT1, 20ug of whole cell protein lysate was loaded onto 8% SDS-PAGE and 
transferred into 0.45um Polyvinylidene Difluoride (PVDF) membranes (Millipore).    To 
detect MMP-3 protein expression, which is a secreted protein therefore expressed best in the 
medium, one million cells were plated in a 10cm dish and were incubated in serum starvation 
conditions with 5ml of serum free MEM for 48hrs.  The supernatant from cell culture was 
concentrated to 100ul. A total of 10ug of protein from the supernatant was loaded onto 10% 
SDS-PAGE.  The membranes were blocked with 5% milk for 1 hour. Blots were incubated, 
usually over-night at 4
o
C, with primary antibodies with the right dilution.  Rabbit polyclonal 
anti-NFAT1 1:1000 (Santa Cruz Biotechnology); Rabbit polyclonal anti-MMP-3 1:1000 
(Abcam), Rabbit polyclonal anti beta-Actin 1:2000 (Santa Cruz). Proteins were detected by 
ECL detection system (GE Healthcare). To confirm equal loading of the supernatant, the 
membrane was coomassie blue stained and destained with 40% methanol, 50% water, and 
10% acetic acid until protein bands were visible.   
 
Matrigel Invasion  Assay   
Matrigel invasion assays were performed using Biocoat Matrigel invasion chambers (BD 
Biosciences). Briefly, 1x10
5
 cells diluted in 500 l of serum-free MEM and were placed on 
top of the upper chamber of the Matrigel plate in triplicates. The lower chamber contained 
MEM supplemented with 20% FBS. Matrigel plates were incubated for 40 h at 37 °C. 
Hema3 stain set was used to stain the cells which migrated to the lower surface of the 
Matrigel filter (Fisher Scientific). Filters were glued on a microscope slide. Pictures from 
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different fields where taken under light microscope and the stained cells were counted and 
statistically analyzed. 
 
In vitro proliferation assay  
One thousand of the cells that were used in this experiment, were plated in each well of a 
ninety six well plates that were used in this experiment (12 repetitions for each sample). The 
cells that were plated were the highly metastatic melanoma cell lines A375SM and WM902B 
NT and NFAT1 shRNA and the low metastatic cells SB2 EV and NFAT1 overexpression. 
The cells were cultured for 5 days in 10% FBS normal growth MEM medium. Cell growth 
was analyzed by the colorimetric MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay that determines relative number of cells based on the conversion of MTT to 
formazan (has a purple color) in viable cells. Each day after plating the cells, MTT (Sigma) 
was added to each well at a 1mg/ml concentration in PBS, 20ul for each well. After addition 
of the MTT, a 2 hr incubation period was applied at 37°C. Medium and MTT were removed 
from the wells and were replaced by 100ul of diametyl sulfoxide (DMSO, Sigma). After 1 hr 
of incubation at room temp with DMSO the plate was read and quantified by measuring 
absorbance at 570nm using Epoch BioTek plate reader. This procedure was repeated daily 
over 5 years in order to compare if there are differences between the proliferation rates of cell 
lines that were NFAT1 manipulated using lentivirous stable transduction.      
 
Reverse transcription-PCR   
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Regular PCR: RNA isolation was performed with the RNAqueous kit (Ambion). One 
microgram of total RNA was reverse transcribed (RT) using the High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems).  One microgram Real time PCR was 
performed with the Taqman Gene Expression Assay and standardized to GAPDH (Applied 
Biosystems).  NFAT1, IL-8 and MMP-3 Taqman Gene Expression Assays were acquired 
from Applied Biosystems and qRT-PCR was performed on A375SM WM902B and SB2 
melanoma cell lines.  Each probe was standardized to one with control sample. 
 
Quantitative Real time PCR (qRT-PCR)   
RNA (20 ng/μl) from the A375SM, WM902B and SB2 cell lines was harvested using a 
mirVana kit (Ambion) according to the manufacturer's instructions. The RNA was then 
transcribed into cDNA using TaqMan reverse transcriptase reagents for general cDNA. The 
primers for NFAT1, IL-8 and MMP-3 and fluorescence probes were obtained from Applied 
Biosystems. Reaction components for reverse transcription-PCR and amplifications were 
described previously [81]. Amplifications were run in triplicates, and averages were obtained 
after normalization with 18s (Applied Biosystems). Data was expressed in -fold change. 
 
Chromatin Immunoprecipitation Assay (ChIP) 
ChIP Assay was performed using ChIP-IT Express Kit (Active Motif) according to the 
manufacturer’s protocol. 1×107 melanoma cells were plated in 15 cm culture dishes. The next 
day cells were fixed with 37% Formaldehyde containing medium. The cells were then 
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scraped from plates, and cell suspensions centrifuged for 10 minutes at 2500 rpm at 4 °C. 
Supernatant was discarded. The cells at the bottom of the tube were then lysed and incubated 
on ice for 30 minutes. Next, chromatin enzymatic shearing was performed to cut the DNA to 
fragments sized between 200-1000-bp. Fixed protein DNA complexes were then pulled down 
using magnetic beads with anti-NFAT1 antibody (Santa Cruz) followed by separation from 
the magnetic beads and Protein-DNA reverse cross-linking at 65°C for 2.5 hours. Next, the 
proteins were digested for one hour at 37°C with of Proteinase K and the DNA was prepared 
for PCR.  PCR was performed by surrounding both NFAT1 binding sites with the following 
primers; NFATF- GCTCAAACTGCCAGCAAAAT and NFATR- 
CACAGGGTGTTCACAAATCG.  The PCR product was run in a 1.5% agarose gel. 
 
Reporter Constructs and Luciferase Activity Analysis   
The IL-8 and MMP-3 promoters were cloned from A375SM melanoma cells to encompass 
851 (IL-8) or 2682 (MMP-3) base pairs upstream of the transcriptional initiation site with the 
following primers respectively; IL-8 Forward-5’- 
GGGGTACCCTGCTCTTATGCCTCCACTG-3’ and Reverse-5’- 
GGAAGATCTCTTGTGTGCTCTGCTGTCTCT-3’ and for MMP-3 Forward-5’- 
GGGGTACCCACTCAGTTGCTCTTTAATTTTACC-3’ and Reverse-5’- 
GGAAGATCTCGCACAGCAACAGTAGGATTG-3’. PGL-3 basic was cut with Kpn1 and 
BglII restriction enzymes and the IL-8 or MMP-3 promoters were inserted.  Direct site 
mutagenesis of NFAT1 binding sites were carried out using QuikChange II XL Site-Directed 
Mutagenesis Kit (Stratagene) according to manufacturer’s instructions.  Cells were plated in 
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a 24 well plate with 2.0 x 10
4
 cells/ well.  After 48 hours, transfection with Fugin 6 
(Promega) was performed according to manufacturer’s instructions.  Briefly, each well was 
transfected with 0.8 μg of the basic pGL3 expression vector with no promoter sequence or 
with 0.8 μg of pGL3 with the inserted IL-8 or MMP-3 promoter; mutations were performed 
in the NFAT1 binding sites.  As a control, 2.5 ng of cytomegalovirus (CMV) driven renilla 
luciferase construct (pRL-CMV, Promega) was included per well. Each group was plated in 
replicates of six.  After 48 hours the cells were lysed and luciferase activity was assayed with 
the Dual Luciferase Reporter Assay System (Promega) according to the manufacturer’s 
instructions.  The ratio of PGL3 firefly to CMV-driven renilla luciferase activity was used to 
normalize each sample.      
 
Immunohistochemistry (IHC)  
Mice were killed and tumors were collected.  Half of each tumor was formalin fixed and 
embedded into paraffin and the other half was frozen at -80°C. Paraffin-embedded
 
tumor 
specimens were mounted on positively
 
charged superfrost plus slides (Fisher Scientific). 
Slides were heated at 56°C for 20 min and de-paraffinized in xylene, hydrated in graded 
ethanol (100%, 95%, and 80%
 
ethanol), and then rehydrated in PBS twice.  Antigen retrieval 
was performed in pepsin (BioCare Medical) at RT for 10 minutes or with citrate buffer 0.1M. 
Endogenous peroxidase was blocked with
 
3% hydrogen peroxide in PBS. Samples were 
exposed to protein block (5% normal horse serum
 
and 1% normal goat serum in PBS) for 20 
minutes and incubated with each primary
 
antibody – rabbit anti-human IL-8 (1:100), rabbit 
anti-human NFAT1 (1:400) and rabbit anti-human MMP-3 (1:100) antibodies overnight at 
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4
◦
C.  Slides were washed, incubated for 10 minutes
 
in protein-blocking solution, and then 
reacted with goat anti-rabbit IgG secondary antibodies (Jackson ImmunoResearch, West 
Grove, PA).  
CD31 staining was executed by the same protocol as procedures of other antibodies, except 
that a goat anti-mouse CD31 (1:200) antibody (PharMingen, San Diego, CA) was used.  
Upon washing with PBS, the signals of specimens were developed with 3,3'-
Diaminobenzidine (DAB) for 5-10 minutes at RT.  The slides were washed with dH2O, air-
dried and applied with cover slides. The photo images were obtained from the Leica 
microscope DFC 320 (Wetzlar, Germany) For CD31 staining, frozen sections were fixed for 
5 minutes in each of the following solutions: acetone, acetone:chloroform (1:1) and acetone. 
Slides were then washed with PBS three times and blocked with protein block 4% Fish 
gelatin in PBS for 20 minutes at room temperature. Slides were incubated at 4°C over night 
with primary antibody (rat anti-mouse CD31, PharMingen Inc. Cat. #01951A). Alexa 494 
[125] was incubated for 1 hour at room temperature. Slides were then washed 3 times for 3 
minutes in PBS.   
 
TUNEL assay  
TUNEL staining was performed utilizing a TUNEL assay kit (Promega, Promega, Madison, 
WI). Slides were fixed in 4% Paraformaldehyde for 10 minutes at room temperature followed 
by two 5 minute washes with PBS. Slides were then incubated in 0.2% Triton X-100 in PBS 
for 15 minutes and washed twice with PBS. Subsequently, slides were incubated with DNase 
for 10 minutes at 37ºC and washed four times with PBS. Equalibrium buffer was then used 
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on slides for 10 minutes at room temperature. Incubation buffer containing 5ul Nucleotide 
Mix and 1 ul of TDT enzyme was then applied on slides. Slides were then incubated at 4°C 
over night. The following day, slides were washed with SSC buffer twice for 15 minutes 
followed by washes with PBS to remove unincorporated Fl-dUTP. Hoechst (Molecular 
Probes, Carlsbad CA) diluted at 1:10,000 in PBS was used to counterstain slides.  
 
Animals  
Female athymic BALB/c nude mice at the age of 8-10 weeks were purchased from Taconic 
(Hudson, NY ). Animals were maintained in facilities approved by the American Association 
for Accreditation of Laboratory Animal Care in accordance with current regulations and 
standards of the United States Department of Agriculture, Department of Health and Human 
Services, and the NIH. All studies were approved and supervised by The University of Texas 
MD Anderson Cancer Center, Institutional Animal Care and Use Committee (IACUC).   
 
In Vivo subcutaneous tumor growth 
Subcutaneous tumors were produced by injecting 0.5-1 x10
6
 tumor cells/100 ul PBS into the 
right frank of each mouse. Between 6 to 8 mice mice were injected for each group. Tumor 
size was monitored twice a week for 27 days. Mice were then sacrificed and tumors were 
collected.  The tumors were processed for IHC to detect alteration of IL-8, MMP-3, CD31. 
TUNEL assays also were performed to determine the effects on vessel density and apoptosis 
of tumors.  
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Experimental Lung Metastasis Assays  
For lung metastasis experiments, 6 to 8 mice per group were injected with 0.5-1x10
6
 tumor 
cells in 100 ul PBS via mouse lateral tail veins as previously described [89]. Tumor 
metastasis burden was closely monitored. Any mouse that demonstrated a sign of thin or 
hunched postures was scarified earlier.  The mice were killed about 6 weeks after injections; 
the lungs were removed, and fixed in Bouin's solution for 24 hours. The number of surface 
tumor nodules were counted using a dissecting microscope.  
 
 
cDNA Microarray 
Total RNA was isolated from A375SM NT and NFAT1 shRNA melanoma cells using 
mirVana Isolation Kit (Life Technologies). RNA was then converted into cRNA using the 
Illumina TotalPrep Amplificatin Kit (Life Technologies) and hybridized to HT-12 Illumina 
chip in triplicates.  Gene expression analysis was performed between NFAT1 NT and 
NFAT1 shRNA samples. 
 
Statistical Analysis 
Student's t test was used to analyze the statistical significance of differences in the in vitro 
data. In the animal studies Mann-Whitney U test was used in the tumor growth and lung 
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metastasis results. Values for tumor growth are given as a mean volume ± S.E.M. P values 
that are smaller than 0.05 were considered statistically significant.  
 
TCGA Analysis 
Statistical analyses were performed in R (version 3.0.1)  (http:///www.r-project.org/) and the 
statistical significance was defined as a p-value less than 0.05.  We downloaded and analyzed 
clinical and mRNA (Level 3 Illumina RNASeqv2)  data publicly available from the Cancer 
Genome Atlas Project (TCGA; http://tcga-data.nci.nih.gov/) for  patients with skin cutaneous 
melanoma  (SKCM).    
For NFAT1 Tumor vs. Metastatic comparison  
The Shapiro-Wilk test determined that NFAT1 (log2 reads) did not follow a normal 
distribution in tumor or metastatic samples.   The nonparametric test Mann-Whitney-
Wilcoxon test was applied to compare NFAT1 expression levels between the two groups and 
a box-and-whisker plot (Box plot represents first [lower bound] and third [upper bound] 
quartiles, whiskers represent 1.5 times the interquartile range) was used to visualize the data.  
For survival IL-8 and MMP-3:  
For each gene of interest, we checked for a relation with the survival as follows.  Patients 
were grouped into percentiles according to mRNA expression.  The Log-rank test was 
employed to determine the association between mRNA expression and overall survival and 
the Kaplan-Meyer method was used to generate survival curves.  Cut-off points (log-rank test 
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p-value <0.05) to significantly split the samples into low/high mRNA groups were recorded. 
The cut-off to optimally separate the patients in high/low (min p-value) was chosen.  
 
Dual IHC Staining for Tissue Microarray (TMA)  
Paraffin sections in 5 μm thickness were made, and immunohistochemistry was performed 
using monoclonal antibodies against NFAT1 (clone D43B1 [1:50 dilution]; Cell Signaling, 
Danvers, MA) and CD8 (Clone C8/144B [1:20 dilution]; LabVision, ThermoFisher). After 
deparaffinization, antigen retrieval was performed using a citrate buffer (pH 6.0) in a 
pressure cooker. Slides were then incubated with NFAT1 antibody, followed by Envision+ 
horseradish peroxidase reagent (Dako, Carpentaria, CA), followed by incubation with 
diaminobenzidine (DAB). After washing, the slides were incubated with CD8 antibody, 
followed by an alkaline phosphatase-conjugated secondary antibody (Bond Polymer Refine 
Red Detection, Leica Biosystems, Buffalo Grove, IL), and then incubated with Fast Red/AP 
chromogen. CD8 (red chromogen) and NFAT1 (brown chromogen) immunoreactivity were 
considered positive if moderate to strong staining was identified in even a single cell. The 
extent of staining was quantified using the following scale: 0 indicated no staining; 1+ 
indicated positive reactivity in < 25% of tumor cells; 2+ indicated positive reactivity in 25-
50% of tumor cells and 3+ indicated positive reactivity in > 50% of tumor cells. Localization 
to the cytoplasm or the nucleus was recorded for all cases expressing NFAT1. CD8 localized 
to the cytoplasm & membrane when expressed.  The TMA that we have used have total  130 
specimens: 59 Nevi, 39 primary and 32 metastatic, each sample is represented twice on the 
block.  
  
39 
 
 
 
 
 
 
 
 
 
CHAPTER 3: Specific Aim 1 
 
To Determine the Status and Contribution of NFAT1 to Melanoma Progression  
1.1 Examine the Status of NFAT1 in Melanoma Progression 
1.2 Study the In Vitro and In Vivo Effects of Silencing NFAT1 in Metastatic Melanoma 
Cell Lines and the Effects of Overexpression NFAT1 in Low Metastatic Cell Lines 
 
Introduction 
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Melanoma is the deadliest form of skin cancer in the United States [2].   During the 
last decade there has been tremendous progress in understanding the genetic changes that are 
associated with melanoma progression.  Those newly discovered target genes can potentially 
help researchers in finding new therapeutic combinations in melanoma. During the 
progression of the disease, melanoma cells need to acquire the ability to invade the basement 
membrane and migrate into the dermis. In our research, we are looking at NFAT1 as a 
potential gene that may be an important protein that helps melanoma cells acquire the 
invasive phenotype. NFAT1 expression has also been associated with cancer; in breast 
cancer patient specimens, higher expression of NFAT1 was recognized with primary tumors 
and lymph node metastasis compared to normal adjacent tissue [112].  By evaluating past 
publications and previous evidence we hypothesized that NFAT1 (besides its role in the 
immune system) can be a key player in the invasive phenotype of melanoma cells. NFAT1 is 
possibly playing an important role in melanoma progression and metastasis formation. In this 
first specific aim we want to determine the contribution of NFAT1 to the In vitro and In vivo 
phenotype of melanoma cell lines and examine the status of NFAT1 in melanoma patients. 
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Sub Aim 1.1: Examine the Status of NFAT1 in Melanoma Progression (Cell Lines and 
Patients) 
 
Results 
Analysis of NFAT1 Expression in a Melanoma Cell Line Panel 
To examine the status of NFAT1 in melanoma progression, a panel of melanoma 
lines ranging from low to highly metastatic were utilized. Using western blot analysis, we 
validated that the more metastatic cell lines they express higher levels of NFAT1, while the 
less metastatic melanoma cells express significantly lower levels of NFAT1.  As shown in 
figure 4, the highly metastatic melanoma cell lines (Mewo, TXM18, A375SM WM2664 and 
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WM902B) expressed higher levels of NFAT1 as compared to the less metastatic melanoma 
cell lines (SB2, and DM4).   Our cell panel can be further divided into two groups: those with 
BRAF mutations (highly metastatic in our case) and those with NRAS mutations (low 
metastatic in our case). When NFAT1 expression was analyzed by this manner, we found 
that cells with BRAF mutations have higher expression levels of NFAT1 and cell lines with 
the NRAS mutations had a lower expression of NFAT1. However, it is possible that this cell 
line panel is not representative. A larger scale analysis should be performed in order to have 
a conclusion about the connection between the BRAF mutations with NFAT1 expression 
levels in melanoma cell lines. Therefore this correlation could be due to the panel lacking 
highly tumorigenic NRAS and non BRAF
V600E
 mutation cell lines.  Later, we also performed 
patients analysis for NFAT1 to confirm.   
 
 
 
 
 
 
 
Figure 4:  NFAT1 is Expressed at Higher Levels in Metastatic Human Melanoma Cell Lines 
Low 
metastatic 
Highly 
metastatic 
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Western blot analysis in melanoma cell lines was performed.  The less tumorigenic SB2, and DM4 
melanoma cell lines express significantly less NFAT1 than the more tumorigenic and metastatic 
Mewo, TXM-18, A375SM, WM2664 and WM902B cells.   
 
 
 
 
 
 
 
 
 
Melanoma TCGA Analysis of NFAT1 
In this set of experiments we sought to validate our observations in melanoma cell lines by 
mining the TCGA (The Cancer Genome Atlas) data for NFAT1 expression. This analysis 
revealed a significant higher expression of NFAT1 in metastatic lesions compared to primary 
melanoma lesions (p=0.0079) (Figure 5). This analysis validated our observation in 
melanoma cell lines that, the more metastatic the cell is, the higher NFAT1 expression it has. 
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Figure 5: Analysis of TCGA Melanoma Data for the Expression of NFAT1 in Melanoma 
Patients Analysis of TCGA revealed a significant overexpression of NFAT1 in the metastatic lesions 
(p=0.0079) compared to primary melanoma lesions. Primary melanoma lesions (n=55), metastatic 
lesions (n=257). 
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Analysis of NFAT1 in a Melanoma Patients’ Tissue Microarray (TMA) 
To further delineate the status of NFAT1 in melanoma progression, the expression of NFAT1 
was examined in tissue samples from melanoma patients in different stages (nevi, primary 
and metastatic). The evaluation was made in a way that the score is given by the expression 
level of NFAT1 on the tumor cells but not on the immune cells. This scoring was achieved 
after double staining for NFAT1 and tumor infiltrating lymphocytes (TIL). The expression 
was evaluated on the tumor cells alone. CD8 (red stain for T cells) and NFAT1 (brown) 
immunoreactivity were considered positive if moderate to strong staining was identified. For 
quantification we used the following scale: 0 indicated no staining; 1+ indicated positive 
reactivity in < 25% of tumor cells; 2+ indicated positive reactivity in 25-50% of tumor cells 
and 3+ indicated positive reactivity in > 50% of tumor cells.   Indeed there was a difference 
between the expression of NFAT1 in metastatic versus primary melanoma patients. The 
metastatic tissues expressed more NFAT1. Unfortunately, the scoring is still in progress but 
from the general trend we can assume that these results support the TCGA analysis and the 
results from the western blot for the cell panel.  
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Figure 6: Analysis of TMA for the Expression of NFAT1 in Melanoma Patients. On this 
array there are 130 human tumor samples. After scoring the expression of NFAT1 on tumor 
cells we can see a significant difference between metastatic and primary melanoma tumors.  
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Sub Aim 1.2 Study the In Vitro and In Vivo Effects of Silencing NFAT1 in Metastatic 
Melanoma Cell Lines and the Effects of Overexpression NFAT1 in Low Metastatic Cell 
Lines 
 
Results 
The Effect of Silencing NFAT1 in metastatic melanoma and overexpressing it in low 
metastatic melanoma cell lines. 
To establish the role of NFAT1 in melanoma progression and in promoting tumor 
growth and metastasis, we chose to stably silence NFAT1 in two metastatic melanoma cell 
lines that have high levels of NFAT1 expression and overexpressing NFAT1 in a low 
metastatic cell line (with low levels of NFAT1). From our cell line panel, the cells that met 
these criteria were the WM902B, A375SM and SB2 melanoma cell lines (Figure 4). The two 
metastatic melanoma cell lines, A375SM and WM902B, were then stably transduced with 
non-targetable (NT) or NFAT1 shRNA packaged lentivirus. NT shRNA has no known 
homolog sequence among human genes; it will be used as a control to verify that the 
transduction by the virus itself did not cause any unexpected changes in the cells. This 
control vector contains green fluorescent protein (GFP) and it will be used throughout the 
study. The SB2 cell line was stably transduced with the NFAT1 overexpression construct and 
for the control we used an empty vector (EV) construct that does not include any inserted 
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gene. The overexpression transduction has a puromycin selection, and in order to select the 
positively transduced cells, the culture was grown with 1mg/ml puromycin for 48hr.  For 
A375SM and WM902B, both NT and NFAT1 shRNA melanoma cells were sorted for the 
top 40% percent of GFP fluorescence, by Fluorescent Activated Cell Sorting (FACS). After 
cell sorting/puromycin selection, WM902B, A375SM and SB2 melanoma cell lines that were 
transduced were expanded in culture. We performed western blot analysis to determine the 
silencing efficiency of NFAT1 shRNA or the overexpression efficiency for NFAT1 over-
expressing vector. By using densitometry and normalizing NFAT1 to actin, it was observed 
that the WM902B and A375SM cell lines have 58% and 75% knock down of NFAT1 
respectively as compared to the NT shRNA control (Figure 7). In SB2 cells, NFAT1 
overexpression results demonstrated infinite fold of NFAT1 overexpression in that cell line 
due to no expression in the parental cells.  These three cell lines were then used throughout 
the study. 
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Figure 7:  Stable Transduction of NFAT1 shRNA/ Overexpressing Vector Efficiently Reduce 
NFAT1 Expression in both WM902B and A375SM and Overexpress it in SB2 Melanoma Cell 
Lines. NFAT1 expression is lost in both melanoma cell lines with the stable lentiviral based 
transduction of NFAT1 shRNA.  Densitometry analysis for WM902B cells confirms that 
approximately 58% of NFAT1 expression is lost.  For A375SM cells, NFAT1 expression is 75% lost. 
For SB2 cells we have a complete overexpression of NFAT1.  
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In Vitro Invasive Phenotype of Melanoma Cells Following NFAT1 Silencing/ 
Overexpression  
To validate that NFAT1 increases the invasive phenotype of melanoma cell lines, 
NFAT1 silenced WM902B and A375SM melanoma cells and SB2 with NFAT1 
overexpression were subjected to the matrigel invasion chamber invasion assay. The cells 
were plated in fetal bovine serum (FBS) free media (MEM) on top of the chamber. The cells 
were incubated for 24 hours. The bottom chamber contained MEM media with 20% FBS to 
act as a chemoattractant. The number of invaded cells through the chamber was evaluated by 
counting equal fields from all membranes. A significant reduction in the number of invaded 
melanoma cells was observed after silencing NFAT1 in both WM902B and A375SM cell 
lines, *p < 0.001 (Figure 8).  A more than 2 fold reduction was observed in WM902B cells 
and more than 3 fold reduction in A375SM.   A significant increase in the number of invaded 
cells was observed after overexpression of NFAT1 in SB2 cells; more than a 5 fold increase 
was observed.  As seen in figure 8, the invasive capacity of melanoma cells is significantly 
reduced after silencing NFAT1 in metastatic cell lines p < 0.001, with more than a 2 fold 
reduction in WM902B and 3 fold reduction in A375SM, and on the other hand, the invasive 
capacity was increased after NFAT1 overexpression in SB2 cells. Therefore, our data support 
the idea that NFAT1 is critical for the invasive phenotype of melanoma cell lines.  To make 
sure that the invasive phenotype indeed changed as a result of NFAT1 expression in the cell 
lines and not due to higher doubling time of the tested cells, we performed MTT proliferation 
assay as presented in figure 9. We found no changes in the doubling time of A375SM and 
WM902B after NFAT1 silencing compare to the NT. Similar results were observed in this 
the SB2 cell line after overexpression of NFAT1.  Since no significant difference was 
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detected in the doubling time, we concluded that the changes in the invasion assay were not 
due to differences in cell division times but due to NFAT1 genetic manipulations which 
influenced on the invasive and migratory phenotype.  
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Figure 8:  The Invasive Phenotype of Melanoma Cells after Silencing /Overexpressing NFAT1 
The invasive phenotype of melanoma cells were analyzed by matrigel invasive chambers 8µm (A) 
The number of invaded cells through the Matrigel invasion chamber is significantly reduced after 
silencing NFAT1 in both WM902B and A375SM melanoma cells as compared to NT shRNA (*P < 
0.001) and on the other side, the number of invaded cells is significantly increased after NFAT1 
overexpression in SB2 cells.  (B) A representative image for each cell line with either NT or NFAT1 
shRNA or NFAT1 overexpression is shown (NT non targeting, OE overexpression). 
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Figure 9: Proliferation Rate of NFAT1 Silenced Metastatic Melanoma Cell Lines or NFAT1 
Overexpression in Low Metastasis Cell Lines. MTT assays were performed to determine doubling 
time of A375SM, WM902B (A,B) cells after transduction with NFAT1 shRNA as compared to NT 
transduced cells, and SB2 after NFAT1 overexpression compared to empty vector control (C).  MTT 
assays determined relative cell numbers based on the conversion of MTT to formazan in viable cells. 
Cell growth was measured daily for 5 days period. No significant differences were found in the 
doubling time in either transduced cell line (P>0.05).   
 
 
 
 
 
 
 
 
 
 
 
 
 
  
56 
 
Determine the In Vivo Effect NFAT1 on Tumor Growth and Experimental Lung 
Metastases  
To determine whether NFAT1 has an effect on melanoma tumor growth and 
metastasis, an in vivo experiment was performed. To that end, we used A375SM highly 
metastatic cells with NFAT1 shRNA compared to NFAT1 NT shRNA and the low metastatic 
SB2 after NFAT1 overexpression compared to SB2 EV (empty vector). 5x10
5
 A375SM cells 
or 1x10
6
 SB2 cells were injected subcutaneously into the right flank of nude mice (n=6 mice 
per group) for tumor growth, or intravenously into the tail vein of the mice (n=6 mice per 
group) for experimental lung metastases. Each group had the control group A375SM NT and 
SB2 EV respectively. The subcutaneous tumors were monitored twice weekly for 31 days for 
A375SM, and for 41 days for SB2 cell lines.  At the end of the measurements the tumor size 
mean of A375SM NT group was 1557mm
3
 compared to 509mm
3
 in the A375SM with 
NFAT1 shRNA (Figure 10A). At day 41, SB2 EV cells had a mean tumor volume of 
428mm
3
 compared to 1125mm
3
 for SB2 NFAT1 OE cells (Figure 10B). We observed a 
significant decrease in tumor growth after silencing NFAT1 and significant increase in tumor 
growth after overexpressing NFAT1 in melanoma cells. Since we already demonstrated that 
there is no difference in the doubling time of these cell lines, we can conclude that the 
differences we observed in tumor growth rates are due to NFAT1 expression. 
For the experimental lung metastasis, A375SM were injected in two groups NT and 
NFAT1 shRNA as well as SB2 EV cells and SB2 NFAT1 OE cells. After 6 weeks, the mice 
were killed and macroscopic lung metastases were counted in all groups. The results showed 
that the number of lung metastases was significantly decreased after silencing of NFAT1 
(mean of 10 mets) in the highly metastatic A375SM cells when compared to the A375SM 
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NT group (mean of 36.17 mets) (Figure 10C), and conversely, the number of lung metastases 
was significantly increased in the SB2 NFAT1 OE group (mean of 36 mets) compared to 
SB2 NFAT1 EV (mean of 11 mets) as presented in figure 10D. The mean number of lung 
colonies of A375SM groups were 36 for NT and 10 for NFAT1 shRNA p<0.01 and 11 for 
SB2 EV and 36 for SB2 NFAT1 OE p<0.001. 
Taken together, NFAT1 silencing, which was achieved through lentiviral shRNA, resulted in 
an inhibition of experimental lung metastasis growth of A375SM metastatic melanoma cells. 
Furthermore, overexpression of NFAT1 in the low metastatic cell line, SB2, resulted in an 
increase of lung metastasis growth, thereby strengthening our hypothesis that NFAT1 is 
essential to melanoma growth and metastasis. 
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     C                                                                                              D 
Figure 10: NFAT1 Expression is Required for the Malignant Melanoma Phenotype  
Silencing NFAT1 in A375SM melanoma cells reduces tumor growth and experimental lung 
metastasis in nude mice while overexpression of NFAT1 in SB2 increases both tumor growth and 
metastasis. (A) A375SM melanoma cells were injected subcutaneously in nude mice and tumor 
growth was monitored for 31 days.  Tumor growth was significantly reduced after silencing NFAT1 
at day 31, tumor volume  mean of 1557mm
3
 compared to 509mm
3
 (*P < 0.05). (B) SB2 melanoma 
cells were injected subcutaneously into nude mice and monitored for 41 days. Tumor growth was 
significantly increased after overexpressing NFAT1, mean tumor volume of 428 mm
3 
compared to 
1125 mm
3
 (*P<0.05) (C) Six weeks after intravenous injection of A375SM cells, nude mice were 
sacrificed and the number of lung metastasis were counted.  Silencing NFAT1 significantly reduced 
the number of experimental lung metastasis, mean of 10mets compared to 36 mets (P* < 0.01). (D) 
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Six weeks after intravenous injection of SB2 cells, nude mice were sacrificed and the number of lung 
metastasis was counted.  Overexpressing NFAT1 significantly increased the number of experimental 
lung metastasis mean of 36 mets compared to 12 mets (P* < 0.001). 
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Silencing NFAT1 Changes the Gene Expression Profile of A375SM Melanoma Cells 
 
To identify potential downstream targets of NFAT1, an Illumina microarray was 
performed (HT-12 Version 3 chip). RNA from three separate 10cm dishes (to confirm 
reproducibility) was isolated from A375SM NT and NFAT1 shRNA cells.  Our data suggest 
that silencing NFAT1 does deregulate various genes in these melanoma cells.  We then 
mined the data to identify novel genes with significant fold changes in the gene expression 
array.  We focused our attention on genes that were down regulated after silencing NFAT1, 
since they were likely to be tumor promoter genes.  The top identified genes then were mined 
and sorted by their relevance to cancer are presented in Table 1. Among these genes that 
were downregulated after NFAT1 silencing, we found follistatin (FST) that has been reported 
as a contributor to bone metastasis [126] and placenta-specific 8 (PLAC8) whose 
overexpression is reported to protect cancer cells from apoptosis [127-129]. Also, frizzeld 
family receptor 4 (FZD4), nicotinamide N-methyltransferase (NNMT). Of the potential 
genes, we decided to focus our research on interleukin 8 (IL-8/CXCL8) and matrix 
metallopeptidase 3 (MMP-3).  IL-8 is known to play an important role in the progression and 
metastasis of several different cancers including melanoma. Our laboratory has previously 
demonstrated that overexpression of IL-8 is associated with increasing tumor stage, disease 
progression, and recurrence in human melanoma.  Furthermore, a direct correlation between 
high levels of IL-8 and tumor angiogenesis, progression, and metastasis in nude mouse 
xenograft models of human melanoma were previously shown [130]. Therefore, we 
hypothesize that NFAT1 may contribute to melanoma tumor growth and metastasis through 
the regulation of IL-8. The second gene that we decided to study as a downstream target of 
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NFAT1 is MMP-3.  MMP-3 was shown to be associated with Alzheimer’s, multiple sclerosis 
and Parkinson’s disease. MMP-3 also contributes to several pathologies such as asthma, 
rheumatoid arthritis and cancer [131].  MMP-3 transcription can be triggered by reactive 
oxygen species (ROS), cytokines, growth factors and cell interactions.  MMP-3 can activate 
cell adhesion molecules, growth factors, chemokines, cytokines and receptors. Likewise, 
MMP-3 is able to activate other MMP family members.  In melanoma MMP-3 has not been 
much studied, and the role of MMP-3 in melanoma progression has yet to be elucidated, 
therefore we decided to study the role of MMP-3 in the metastatic melanoma phenotype. 
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Table 1: Top Potential Genes Down Regulated after Silencing NFAT1 
The top potential candidate genes are shown.  These genes were downregulated after silencing 
NFAT1 in A375SM melanoma cells as compared to the non-targeting (NT) control. Note that our 
gene expression array confirmed that after NFAT1 silencing, autotaxin was reduced by almost 3 fold 
as was published by our lab before [122]. The two genes of interest IL-8 and MMP-3, are 
downregulated by 2.4 and 3.22 fold respectively.   
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Summary Specific Aim 1  
Herein, we report that there is a positive correlation between the metastatic potential 
of the melanoma cell lines and the expression level of NFAT1. The more metastatic the cell 
is, it correlates with higher NFAT1 expression level. Furthermore, from TCGA data analysis, 
we found that specimens from metastatic patients demonstrated significantly higher 
expression of NFAT1 compared to patients with primary tumors. These results support our 
observations in the cell lines. We validated these results by staining our own in house TMA.   
Also, we showed that silencing NFAT1 in two metastatic melanoma cell lines, WM902B and 
A375SM, significantly reduced the invasive potential of these cell lines, while 
overexpression of NFAT1 increases the invasiveness of SB2 cells; although these 
manipulations did not change the proliferation ability of the cell lines. The role of NFAT1 in 
melanoma tumor growth and experimental metastasis was also examined by utilizing an in 
vivo study. The in vivo studies confirmed that the expression of NFAT1 in the melanoma 
cells is important for the progression of the disease. In the presence of NFAT1 the tumor 
growth and the number of experimental lung metastasis were higher. After confirming that 
NFAT1 is necessary for the metastatic potential of the cells, we performed gene expression 
profiling in an attempt to identify potential NFAT1 downstream target genes that might be 
playing important roles in melanoma progression. In the next chapter we will concentrate on 
the link between NFAT1 regulation of IL-8 and MMP-3 expressions.    
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CHAPTER 4: Specific Aim 2 
 
To Identify Novel NFAT1 Downstream Target Genes that Contribute to the Metastatic 
Melanoma Phenotype 
 
2.1 Study NFAT1 as a Potential Regulator of IL-8 Expression in Melanoma Cells  
2.2 Study NFAT1 as a Potential Regulator of MMP-3 Expression in Melanoma Cells  
2.3 Determine the Contribution of MMP-3 to Melanoma Growth and Metastasis 
 
Introduction 
We have demonstrated that NFAT1 silencing in A375SM significantly reduced tumor 
growth and experimental metastasis in vivo when compared to the NT control group (Figure 
10 A,C). We have also demonstrated that overexpressing NFAT1 in the low metastatic SB2 
cells increased their invasion in vitro as well as incresed tumor growth and their metastastic 
potential in vivo (Figure 10 B,D) . Next we wanted to identified downstream target genes of 
NFAT1 and determine the mechanism by which NFAT1 regulates these genes.   From cDNA 
microarray studies, we identified that NFAT1 silencing in A375SM resulted in a significant 
decrease of several downstream gene targets as presented in Table 1. These genes may 
contribute to the metastatic phenotype of melanoma. Among these genes that were 
downregulated after NFAT1 silencing we found follistatin (FST), which has been reported as 
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a contributor to bone metastasis [126], placenta-specific 8 (PLAC8), whose overexpression is 
reported to protect cancer cells from apoptosis [127-129]. Also frizzeld family receptor 4 
(FZD4), nicotinamide N-methyltransferase (NNMT) and others were downregulated.  In our 
research we decided to concentrate on two genes that were downregulated after NFAT1 
silencing, interleukin 8 (IL-8) and matrix metallopeptidase 3 (MMP-3). Previous data 
indicated that NFAT1 can have a major effect on the transcriptional regulation of a variety of 
genes. In breast cancer it was found that NFAT1 promotes breast cancer cell invasion 
through the induction of COX-2 [114]. In breast cancer it was also found that there is a 
negative cross talk between Stat5 and NFAT1 signaling cascades, which may affect breast 
tumor growth and metastasis [112]. NFAT1 has also been shown to support tumor induced 
anergy of CD4
+
 T cells [119]. In this aim, we wanted to identify novel downstream genes 
regulated by NFAT1 that may contribute to melanoma growth and metastasis. To that end, a 
gene expression microarray (Illumina) was performed.  Our microarray data has identified 
many potential target genes including IL-8 and MMP-3 and many others.  The regulation of 
IL-8 and MMP-3 by NFAT1 has not been described yet.  Therefore, we chose to concentrate 
on these two target genes and clarify the link between NFAT1, IL-8 and MMP-3 and their 
contribution to melanoma progression. 
Unfortunately, increasing melanoma incidence has led to a growing number of patient 
deaths due to the aggressive nature of melanoma which commonly metastasizes to the lymph 
nodes, lung, liver, and brain [132, 133].  Currently, less than 10% of patients presented with 
malignant melanoma survive longer than 5 years [2].  Therefore, other treatment modalities 
besides targeting BRAF are needed. Of note, more than 50% of melanoma patients do not 
harbor the BRAF
V600E
 mutation. 
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One of these potential molecules is the chemokine IL-8 (CXCL8).  It has been shown 
that IL-8 expression is positively correlated with melanoma progression [134-136].  
Chemokines are 8-14 kDa signaling proteins that bind to their seven membrane spanning G 
protein-coupled receptors. Chemokines are classified by the position of two conserved cys 
residues at the N-terminal.  These families include the CXC, CC, C, and CX3C chemokines 
[134].  IL-8 is a 8-kDa protein that belongs to the CXC chemokine family. Chemokines were 
initially identified as chemoattractants for leukocytes, however, their expression and 
corresponding receptors have been observed in multiple cell types [134].  In melanoma, IL-8 
was the first chemokine shown to facilitate cancer cell migration.  The overexpression of IL-
8 in melanoma cells up-regulates the expression and activity of the matrix metalloproteinase 
MMP-2, which in turn contributes to a more invasive phenotype [137].  IL-8 binds to its 
receptors CXCR1 and CXCR2 (located on both melanoma and endothelial cells), thus 
promoting tumor growth and angiogenesis [137-140]. Due to the pro-tumorigenic and 
survival- dependent effects of IL-8 in cancer, targeting IL-8 could be therapeutically 
beneficial for melanoma patients.  Previously our lab has shown that neutralizing IL-8 with a 
fully human antibody, ABX-IL8, can significantly reduce tumor growth and experimental 
metastasis of A375SM and TXM-13 melanoma cells [141]. IL-8 has been shown to promote 
the growth, invasiveness, motility, angiogenesis, and metastatic potency of melanoma cells 
[137, 141-143].  Furthermore, our lab has also demonstrated that neutralizing IL-8 ABX-IL-8 
inhibited melanoma growth and metastasis in vivo, mostly by inhibiting angiogenesis [141].  
Interestingly, targeting IL-8 reduced MMP-2 expression, and incubation of melanoma cells 
with ABX-IL-8 reduced the invasive potential of melanoma cells through Matrigel coated 
membranes.  Decreased CD31 staining in vivo and HUVEC tube formation in vitro was also 
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observed [141]. In a new study in the lab, we utilized a siRNA delivery approach to silence 
IL-8 to reduce melanoma growth and metastasis in vivo.  In the present study we want to 
further understand the regulation mechanism of IL-8 during melanoma progression by the 
NFAT1 transcription factor. 
Matrix metalloproteinases (MMPs) are a family of zinc-dependent proteases. The 
proteins in this family have the ability to degrade extracellular matrix components such as 
collagen, gelatin, elastin and casein [144]. Matrix metalloproteinase 3, (MMP-3) which is 
also known as stromelysin-1, is a member of the MMP family. It is known to cleave 
extracellular components including different types of collagens ( types III, IX, and X) [145]. 
MMP-3 has been associated with Alzheimer’s, multiple sclerosis and Parkinson’s disease. 
MMP-3 also contributes to several pathologies like asthma, rheumatoid arthritis and cancer 
[131].  MMP-3 transcription can be triggered by reactive oxygen species (ROS), cytokines, 
growth factors and cell interactions.  MMP-3 has many substrates. Besides extracellular 
matrix (ECM) proteins, it can activate cell adhesion molecules, growth factors, cytokines, 
chemokines, cytokines and receptors. Likewise, MMP-3 is able to activate other MMP 
family members.  Secreted MMP-3 can be activated extracellularly and then transported back 
into the cell [131].  In melanoma, MMP-3 was investigated as a potential serum marker and 
the levels of MMP-3 in the serum were evaluated between healthy patients and malignant 
melanoma patients, but no significant difference was found [146, 147].  
Melanoma progression is a multistep cascade, which requires chemokines, angiogenic 
factors, adhesion molecules and proteases. Several studies suggested that the metastatic 
potential of melanoma is influenced by elastin, which is considered to be one of the most 
important ECM components, especially on the wall of blood vessels and in the lung. MMP-2 
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and MMP-3 degrade elastin proteins, and overexpression of these two genes is correlated 
with aggressive melanoma and poor clinical outcome [148, 149]. It was shown that higher 
stage melanoma is associated with higher levels of elastin, and that the interactions between 
the elastin peptides and the melanoma cells are key for melanoma progression [148, 150]. 
Another study in the field reported that Angpt2, MMP-3 and MMP-10 are all upregulated in 
the lung due to the primary B16F10 tumor in mice [151]. The lung microenvironment could 
be critical for presenting the pre metastatic niche that resulted from the influence of the 
primary tumor. Further, it has been shown that Angpt2, MMP-3 and MMP-10 have a 
synergistic effect on vascular destabilization that promotes the extravasation of melanoma 
cells and supports lung metastasis [151].  Recently SOX2, an embryonic stem cell 
transcription factor, was found to be expressed in human melanoma cells [152, 153]. It was 
also found that after silencing SOX2 in melanoma cells, the expression of MMP-3 was 
reduced by almost 90% [154]. From the association between SOX2 and MMP-3 it was 
evident that MMP-3 is regulated by SOX2 and that their co-expression may be used as a 
functional biomarker for invasive melanoma cells [154].            
As per our knowledge, this study is the first to identify that NFAT1 is a positive 
regulator of MMP-3 and IL-8 expression in melanoma, thus adding a posible mechanism of 
how NFAT1 contributes to melanoma progression. Furthermore, this is the first study to 
demonstrate the importance of MMP-3 in melanoma growth and metastasis.  
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Sub Aim 2.1: Study NFAT1 as a Potential Regulator of IL-8 Expression in Melanoma 
Cells  
 
Results 
IL-8 Expression is Reduced in Melanoma Cells after Silencing NFAT1, and Increased 
after Overexpressing NFAT1 
To validate our gene expression microarray, qRT-PCR and ELISA assays were performed. 
To identify IL-8 expression, the A375SM and WM902B highly metastatic melanoma cells 
were transduced with NT or NFAT1 shRNA while the SB2 low metastatic cell line was 
transduced with EV and NFAT1 overexpression.  To check that the downstream targets are 
not changing due to off target effects after transduction we also performed rescue experiment 
where the cells containing NFAT1 shRNA were transduced with an NFAT1 rescue vector 
(Figure 11). The rescue construct does not contain the sequence recognized by the NFAT1 
shRNA. As seen in figure 11, stable transduction of A375SM and WM902B NFAT1 KD 
cells with NFAT1 rescue vector, NFAT1 expression levels were upregulated. Silencing of 
NFAT1 in both melanoma cell lines, A375SM and WM902B, resulted in ~25% decrease in 
mRNA expression of IL-8 (Figure 12 A,B). IL-8 mRNA expression was observed to be 
reverted to initial levels and even more so when the rescue of NFAT1 experiment was 
performed in both cell lines. In SB2 cells that were overexpressed with NFAT1 we noticed a 
significant increase in mRNA levels (~100 fold) compared to the EV control group (Figure 
12C). Since IL-8 primarily a secreted protein, this can be an explanation for why the whole 
cell lysate western blots did not detect IL-8.  Therefore, the supernatant of melanoma cells 
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was collected from all three manipulated cell lines after 48hr incubation in serum free media 
and was subjected to ELISA assay.  As shown in Figure 13, silencing NFAT1 significantly 
reduced the amount of IL-8 within the supernatant by ~ 4 fold in WM902B cells and ~2.5 
fold in A375SM cells (Figure 13). Also, IL-8 protein levels were significantly increased in 
SB2 cells after NFAT1 overexpression compared to the EV control by more than 10 fold.  
These results from the ELISA assay show that the protein was correlated to the mRNA levels 
of IL-8 after NFAT1 silencing or NFAT1 overexpression as presented in figure 12.  In figure 
11, the western blot from the rescue experiment is presented. In both A375SM and WM902B 
cell lines, we can see clearly more than 5 fold rescue of NFAT1 compare to the actin 
expression. Taken together we conclude that IL-8 is being regulated by NFAT1 both at the 
mRNA and protein level and that rescue of NFAT1 in NFAT1 silenced cells also rescues the 
expression of IL-8. 
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Figure 11: Rescue Experiment of NFAT1 
In order to make sure that the effects of NFAT1 silencing is not a result of off target influence due to 
the virus transduction we utilized rescue cell lines for A375SM and WM902B. These cell lines were 
used to check downstream targets IL-8 and MMP-3 to see that indeed rescue of NFAT1 is also 
rescuing the expression of the downstream targets.   The western blot demonstrated NT (control), 
NFAT1 shRNA, then the EV, which represents the control for the overexpression vector that was 
transduced into the silenced cells and then the rescue of the expression of the NFAT1 and last the 
NFAT1 RES. In both cell lines we can see clearly more than a 5 fold rescue of NFAT1 compared to 
the actin expression (NFAT1 140KDa, β actin 42KDa). 
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Figure 12:  Relative mRNA Expression of NFAT1, IL-8 and MMP-3. Real time PCR results 
showing the relative expression change in the mRNA levels of the downstream targets after 
manipulating NFAT1, silencing it and rescuing it. Genes that were checked are NFAT1, for 
manipulation verifications, and both downstream targets IL-8 and MMP-3 (A) A375SM melanoma 
cell line (B) WM902B melanoma cell lines (C) SB2 cell lines after overexpression of NFAT1 
compared to the control.  
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Figure 13:  Rescue of NFAT1 Rescues the Protein Levels of Secreted IL-8. ELISA assay for the 
secreted protein IL-8. Results demonstrate that after NFAT1 silencing; the levels of IL-8 are 
downregulated and when we rescued the expression of NFAT1 the levels of IL-8 are also rescued in 
both A375SM and WM902B melanoma cell lines. SB2 overexpressing NFAT1 caused upregulation 
of IL-8 expression.    
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NFAT1 Enhances the Promoter Activity and Expression of IL-8 
To further understand the mechanism by which NFAT1 is regulating IL-8 we performed 
ChIP assays to verify the binding of NFAT1 to the promoter of IL-8. First, we identified a 
binding site of NFAT1 on the IL-8 promoter at 32 base pairs from the transcription initiation 
site (TIS). We expect that the reduced IL-8 mRNA and protein expression after silencing 
NFAT1 will be a result of NFAT1 not binding to the IL-8 promoter.  To that end, we tested 
whether NFAT1 binds to the IL-8 promoter and if silencing or overexpressing NFAT1 
affects the binding, by utilizing the chromatin immunoprecipitation (ChIP) assay.  We used 
an anti-NFAT1 antibody to IP DNA-NFAT1 complexes in our engineered melanoma cells 
(A375SM, WM902B NT/NFAT1 shRNA and SB2 NFAT1 EV and OE).  End point PCR 
was performed on the area surrounding the region of NFAT1 binding site on the IL-8 
promoter.  As shown in Figure 14A, NFAT1 binds to the promoter of IL-8 in both A375SM 
and WM902B melanoma cell lines.  When NFAT1 is silenced, no binding to the IL-8 
promoter was detected in both melanoma cell lines. Also, when NFAT1 was overexpressed 
in SB2, we observed a strong band demonstrating the binding of NFAT1 to the binding site 
(Figure 14A).   
The chromatin immunoprecipitation confirms that NFAT1 indeed binds to the IL-8 promoter.  
NFAT1 binding is lost after silencing in A375SM and WM902B and a gain in binding was 
observed in the SB2 cells after overexpressing NFAT1.  To elucidate the role of NFAT1 in 
regulating IL-8 at the transcriptional level, a dual luciferase promoter assay was used. The 
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assay was designed in a way that the IL-8 promoter was cloned in front of the luciferase. The 
promoter was designed with and without mutations in the IL-8 promoter binding site at 
location 32.  Silencing NFAT1 resulted in ~40% reduction of luciferase activity with the wild 
type promoter (Figure 15A,B).  When the mutated promoter was inserted into NT shRNA 
melanoma cells, the luciferase activity was reduced to ~50% of the wild type promoter. The 
mutation also had an effect on luciferase activity in NFAT1 silenced melanoma cells as 
compared to the wild type promoter (Figure 15 A,B).  Therefore, we concluded that our 
reduced promoter activity (after silencing NFAT1) is a direct result of reduced binding of 
NFAT1 protein to the IL-8 promoter. Overexpression of NFAT1 in SB2 resulted with a 
significant increase in the IL-8 promoter activity (Figure 15 C).   
Our initial microarray and qRT-PCR studies confirmed that NFAT1 regulates IL-8 
expression at the mRNA level. ELISA assay demonstrated that the secreted protein levels are 
also regulated by NFAT1.  Furthermore, we also demonstrated that NFAT1 is directly 
binding to the IL-8 promoter by ChIP and Luciferase assays. 
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A.  
 
 
 
 
 
B. 
 
 
Figure 14:  NFAT1 binds to the Promoter  Region of  IL-8 (A) Chromatin immunoprecipitation of 
NFAT1 on the IL-8 promoter is lost when NFAT1 is silenced in A375SM and WM902B cells, 
binding is increased when NFAT1 is overexpressed in SB2 cells (B) One NFAT1 binding site is 
located on the IL-8 promoter within the first 100bp of the transcription initiation site. (red square 
represent NFAT5 binding site)   
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Figure 15:  Dual Luciferase Promoter Activity is Reduced in the Presence of NFAT1 Binding 
Site Mutations. (A,B) Silencing NFAT1 in both A375SM and WM902B significantly reduced the 
luciferase promoter activity of the wild type promoter by approximately 50%  as compared to NT 
shRNA ; P < 0.05.  Mutating NFAT1 binding site at location 32 resulted in reduced promoter activity 
to at least 50% of the wild type promoter; P < 0.05. (C) NFAT1 overexpression in SB2 cells increased 
luciferase promoter activity.  
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Sub Aim 2.2: Study NFAT1 as a Potential Regulator of MMP-3 Expression in 
Melanoma Cells  
 
Results 
MMP-3 Expression is Reduced in Melanoma Cells after Silencing NFAT1 and 
Increased after Overexpressing NFAT1 
To identify downstream targets of NFAT1, cDNA microarray was performed in A375SM 
metastatic melanoma cell line after NFAT1 silencing. Among the genes that were 
downregulated, MMP-3 (also known as stromalysin-1) was downregulated by more than 3 
fold after NFAT1 silencing.  In order to validate the cDNA results, A375SM and WM902B 
metastatic melanoma cell lines, which express high levels of NFAT1, were stably transduced 
with a NFAT1 lentiviral shRNA construct and western blot analysis was performed to 
demonstrate the NFAT1 silencing. The results demonstrated that NFAT1 expression was 
reduced by 75% in A375SM and in 58% in WM902B cells.  Furthermore, SB2 cells that 
express low NFAT1 levels, were transduced with an overexpression vector for NFAT1 
(Figure 7). The MMP-3 gene was recognized as a downstream target of NFAT1 after a 
cDNA array was performed on A375SM NFAT1 silenced cells. From the array data we can 
see more than a 3 fold reduction in MMP-3 expression after NFAT1 silencing (Table 1). For 
further validation, western blot analysis for MMP-3 was performed after silencing NFAT1 in 
A375SM and WM903B as well as after overexpressing NFAT1 in SB2 cells. Since MMP-3 
is a secreted protein, in addition to a whole cell lysate western blot, we also performed a 
western blot for the medium of the cells. The western blots were done using protein from 
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whole cell lysate and from concentrated medium after the cells were serum starved for 48hr. 
The results of the western blot revealed a 50% decrease in A375SM and a 15% in WM902B. 
When the protein was extracted from whole cell lysates, a 40% reduction in A375SM and 
65% reduction in WM902B was observed when the protein was obtained from conditioned 
media. After NFAT1 overexpression in SB2 cells, an increase of 48% in the expression of 
MMP-3 was observed when protein extract was generated from conditional media and 33% 
in whole cell lysate (Figure 16). The densitometry for the whole cell lysates was analyzed 
compared to actin and for conditional media, it was compared to a media loading control.  
Taken together, the secretion of MMP-3 is decreased after silencing NFAT1 and the opposite 
results were observed in SB2 after NFAT1 overexpression. The secretion of MMP-3 
increases after overexpressing NFAT1 in the low metastatic cell lines (Figure 16). 
Furthermore, since MMP-3 is a secreted protein, an ELISA assay was performed (Figure 17).  
In the ELISA assay we included A375SM and WM902B cell lines both after NFAT1 
silencing and after rescue of NFAT1. The rescue of NFAT1 also rescued the expression of 
MMP-3, demonstrating that the downregulation of MMP-3 after NFAT1 silencing is not an 
off target effect but directly regulated by NFAT1. We also included the SB2 low metastatic 
cells in which NFAT1 was overexpressed. The ELISA results showed a significant reduction 
of MMP-3 secretion after NFAT1 silencing in both A375SM and WM902B. To further 
validate that indeed the downregulation of MMP-3 is directly regulated by NFAT1 silencing 
and not from off target effects, we rescued NFAT1 in both A375SM and WM902B cell lines 
(Figure 11). After NFAT1 rescue there was a complete rescue of the MMP-3 secretion, 
where the secretion levels returned back to NT levels in both cell lines. In SB2 cells we can 
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see a significant increase in MMP-3 secretion levels after NFAT1 overexpression in both 
western blot and the ELISA assays (Figure 16, Figure 17). 
Rescue of MMP-3 in Melanoma Cells Results in the Rescue of NFAT1 
Lentiviral based shRNA is a very powerful and useful tool for silencing target genes.  
However, using this method may cause nonspecific effects. These effects are possible results 
of antiviral response to the double stranded mRNA or can be due to targeting different genes. 
To rule out these effects, and to make sure our shRNA construct is on target for NFAT1, 
NFAT1 was rescued in both A375SM and WM902B melanoma cell lines.  We were able to 
rescue NAFT1 successfully in both cell lines as presented in figure 11. The NFAT1 
overexpression resulted in re-expression of MMP-3 in both cell lines while the empty vector 
(EV) control had no effect on these genes as demonstrated by qPCR in figure 12 and by the 
ELISA assay presented in figure 17. Therefore, we concluded that the regulation of MMP-3 
by NFAT1 is not generated due to an off target effect of the shRNA construct, but occurs 
through NFAT1.    
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Figure 16:  Silencing NFAT1 Decreases MMP-3 Expression in Melanoma Cells. Western blot 
using MMP-3 antibody to learn about protein levels. The results show approximately a 40-65% 
reduction of MMP-3 expression within the supernatant in A375SM and WM902B respectively.  
Coomassie blue staining of the membrane was used to confirm equal loading of the supernatant.  
Overexpression of NFAT1 in low metastatic SB2 melanoma cells increases the expression of MMP-3 
in the supernatant by approximately 50%. 
 
 
 
  
Densitometry              1               1.48            1              0.6                 1              0.35      
Densitometry              1               1.33            1              0.5             1              0.85      
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Figure 17:  Rescue of NFAT1 Rescues the Protein Levels of Secreted MMP-3. ELISA assay for 
the secreted protein MMP-3. Results demonstrate that after NFAT1 silencing, the levels of MMP-3 
are downregulated and when we rescue the expression of NFAT1, the levels of MMP-3 are also 
rescued in both A375SM and WM902B melanoma cell lines. SB2 overexpressing NFAT1 caused 
upregulation of MMP-3 expression.    
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NFAT1 Enhances the Promoter Activity of MMP-3 
Our cDNA microarray results indicated that NFAT1 regulates MMP-3 in the mRNA level 
(Table 1). However, we had yet to determine whether this is a transcriptional regulation. To 
answer that question we performed qRT-PCR and as observed the expression of MMP-3 
mRNA was decreased by ~5 fold in both NFAT1 silenced A375SM and by ~3 fold in 
WM902B NFAT1 KD melanoma cells (Figure 12A,B), corroborating the cDNA microarray 
results. For the SB2 low metastatic cell line in which NFAT1 was overexpressed, an increase 
of ~7 fold was observed in MMP-3 expression (Figure12 C). These results demonstrate that 
NFAT1 regulates MMP-3 in the transcriptional level. Since NFAT1 is a transcription factor 
we reasoned that the reduced MMP-3 protein expression after silencing NFAT1 is due to less 
binding of NFAT1 to the MMP-3 promoter.  To that end, we utilized chromatin 
immunoprecipitation assay using an anti-NFAT1 antibody to pull down NFAT1-DNA 
complexes in A375SM, WM902B and SB2 melanoma cells. End point PCR was performed 
on the surrounding area of the first NFAT1 binding site on the MMP-3 promoter, which is 
located at -414bp from the transcription initiation site. NFAT1 binds to the promoter of 
MMP-3 in both A375SM and WM902B melanoma cells.  When NFAT1 is silenced (NFAT1 
KD), no binding to the MMP-3 promoter in both melanoma cell lines was observed (Figure 
18A). In SB2 the binding was observed after overexpressing NFAT1 in the cells and was not 
observed in the empty vector control cells (Figure 18A). The ChIP assay confirms that 
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NFAT1 binds to the MMP-3 promoter and that binding is lost after NFAT1 silencing.  
However, it was not yet clear if NFAT1 directly binds to the MMP-3 promoter, which 
binding site is more significant and if that binding had an effect on transcriptional activation. 
To further determine the regulation mechanism, the dual luciferase promoter assay was used. 
MMP-3 promoter (-1500 to the TIS) was cloned in front of the luciferase reporter gene. The 
luciferase activity driven by the MMP-3 promoter and was significantly decreased after 
NFAT1 silencing, ~4 fold in A375SM and ~7 fold in WM902B (Figure 19 A,B). In NFAT1 
overexpressing cells, the promoter activity of SB2 was significantly increased (~3 fold), after 
NFAT1 overexpression (Figure 19 C). These results indicate that NFAT1 regulates MMP-3 
at the transcriptional level. To further prove that NFAT1 directly binds to the MMP-3 
promoter we generated luciferase constructs with mutations which were inserted into the 
binding sites. Three constructs were made, the first has a mutation in the first binding site, 
MMP3-mut1 (site 414), the second construct had a mutation in the second binding site 
MMP3-mut2 (site 1291) and the third construct had mutations in both binding sites MMP3-
ded (‘ded’ stand for double edited, mutations in both sites). When the mutations were 
inserted, there was a significant decrease in luciferase activity in the control samples 
(A375SM NT, WM902B NT). Interestingly, both mutations had approximately the same 
effect (no significant different was observed) on the promoter activity and the dual mutation 
had no additive effect (Figure 19).  These results suggest that both sites are equally important 
for the transcription activation of MMP-3.    
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B. 
 
 
 
Figure 18:  NFAT1 binds to the Promoter  Region of  MMP-3 (A) Chromatin 
immunoprecipitation of NFAT1 on the MMP-3 promoter is lost when NFAT1 is silenced in A375SM 
and WM902B cells, binding is increased when NFAT1 is overexpressed in SB2 cells (B) Two 
NFAT1 binding sites are located on the mmp-3 promoter within the first 1500bp of the transcription 
initiation site. First site is at -414bp, second site at -1291bp.   
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Figure 19:  Dual Luciferase MMP-3 Promoter Activity is Reduced in the Presence of NFAT1 
Binding Site Mutations. Silencing NFAT1 in both A375SM and WM902B significantly reduced the 
luciferase promoter activity of the wild type promoter by approximately 75% as compared to NT 
shRNA.  Mutating NFAT1 binding sites (each one separately or both) resulted in reduced promoter 
activity compared to the wild type promoter; P < 0.05. (A) A375SM melanoma cells (B) WM902B 
melanoma cells after silencing NFAT1 (C) SB2 melanoma cells after overexpressing NFAT1.   
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Sub Aim 2.3: Determine the Contribution of MMP-3 to Melanoma Growth and 
Metastasis 
 
Results 
MMP-3 Expression is Positively Correlated in Melanoma cell lines 
Although we already identified that MMP-3 mRNA and protein levels are reduced after the 
silencing of NFAT1, we have yet to determine whether the expression levels of MMP-3 has 
any relevance in melanoma growth and metastasis. To our knowledge, the correlation 
between MMP-3 and metastatic potential was not yet established for melanoma. To study 
whether MMP-3 expression is correlated with the metastatic potential of the cell lines we 
used ELISA assay to measure MMP-3 secretion from a panel of cell lines.  The cells that 
were used in this panel are the same cells that we used in the NFAT1 panel: SB2, DM4, 
Mewo, TXM18, A375SM, WM2664 and WM902B.  The results from the ELISA 
demonstrated a direct correlation between the metastatic potential of the cell lines and MMP-
3 secretion.    
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Figure 20: Positive Correlation between the Metastatic Potential of Melanoma Cell Line to 
MMP-3 protein Expression. ELISA assay for a panel of melanoma cell lines used in our lab. The 
less tumorigenic SB2, and DM4 melanoma cell lines they secreted significantly less MMP-3 than the 
more tumorigenic and metastatic Mewo, TXM-18, A375SM, WM2664 and WM902B cells. These 
results correlate with the western blot analysis for NFAT1 expression in the same panel of cells that is 
presented in Figure 4.   
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The Overexpression of MMP-3 Rescues Tumor Growth and Metastasis In Vivo 
To study the role of MMP-3 in melanoma growth and metastasis, we decided to overexpress 
MMP-3 in the SB2 low metastatic cell line, which expressed low levels of MMP-3, and 
silence MMP-3 expression in A375SM, a highly metastatic cell line with high expression of 
MMP-3. We generated a stable SB2 cell line with high levels of MMP-3, and stable A375SM 
cell lines with silenced MMP-3. The expression of the MMP-3 was validated using ELISA 
assay, as presented in figure 21. These cells (A375SM NFAT1 shRNA, SB2 NFAT1 
overexpression) were then injected both subcutaneously and intravenously into nude mice to 
investigate tumor growth and experimental lung metastasis assays respectively. As control 
groups A375SM NT and SB2 EV cells were injected. Tumor volume was measured for 28 
days for the following injected groups; A375SM NFAT1 shRNA vs. A375SM NT and SB2 
NFAT1 OE vs. SB2 EV. As seen in figure 22, our in vivo studies demonstrate that MMP-3 is 
an important player in melanoma tumoregenicity.  Indeed, 3 weeks from injections, there was 
a significant difference in the tumor size.  In A375SM the control group (A375SM NT) 
presented a higher tumor volume than A375SM MMP-3 shRNA. At day 28 the tumor size of 
the control group reached a mean of 1100mm
3
 while the tumor size, after silencing MMP-3, 
had a mean of only 450mm
3
 (Figure 22A). Accordingly we found that overexpression of 
MMP-3 in SB2 cells increased their tumor growth. The MMP-3 overexpression group 
presented a mean of 700mm
3
 at day 28 compared to a mean of 200mm
3
 in the empty vector 
group (Figure 22B). The results for the experimental lung metastasis also supported the 
hypothesis that high levels of MMP-3 contribute to a higher number of experimental lung 
metastases. We found that the mean number of lung metastases derived from A375SM NT 
was significantly higher when compared to the A375SM MMP-3 shRNA group (mean of 56 
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compared to 25 respectively). The differences in the number of lung metastases were also 
significant in the SB2 group. The number of lung metastasis after overexpressing MMP-3 
was higher than the empty vector control group (mean of 9 compared to 4). Taken together, 
we conclude that MMP-3 expression is a contributor for the malignant phenotype of 
melanoma cell lines.   
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Figure 21:  MMP-3 ELISA Demonstrating a Verification of MMP-3 Silencing in A375SM and 
MMP-3 Overexpression in SB2 Cells. ELISA assay for the secreted protein MMP-3. Results 
demonstrate a successful silencing of the protein levels of MMP-3 with both targets (KD1,KD2). 
Results also demonstrate a significant overexpression of MMP-3 in SB2 cells (*P<0.05).  
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Figure 22: MMP-3 Expression is Required for Melanoma Tumor Growth and Metastasis In 
Vivo  
Silencing MMP-3 in A375SM melanoma cells reduces tumor growth and experimental lung 
metastasis in nude mice while overexpression of MMP-3 in SB2 increases both tumor growth and 
metastasis. (A) A375SM melanoma cells were injected subcutaneously in nude mice and tumor 
growth was monitored for 28 days.  Tumor growth was significantly reduced after silencing MMP-3 
at day 28, tumor volume  mean of 1100mm
3
 compared to 450mm
3
 (*P < 0.05). (B) SB2 melanoma 
cells were injected subcutaneously into nude mice and monitored for 28 days. Tumor growth was 
significantly increased after overexpressing MMP-3; mean tumor volume of 200 mm
3 
compared to 
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700 mm
3
 (*P<0.05) (C) Six weeks after intravenous injections of A375SM cells, nude mice were 
sacrificed and the number of lung metastasis were counted.  Silencing MMP-3 significantly reduced 
the number of experimental lung metastasis; mean of 56mets compared to 25 mets (P* < 0.05). (D) 
Six weeks after intravenous injections of SB2 cells, nude mice were sacrificed and the number of lung 
metastasis was counted.  Overexpressing MMP-3 significantly increased the number of experimental 
lung metastasis; mean of 4 mets compared to 9 mets (P* < 0.01). 
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Immunohistochemistry for the Expression of Downstream Targets In Vivo 
We next investigated the expression of IL-8, MMP-3 and CD31 at the tumor level using 
immunohistochemistry of the tumor sections from the in vivo study (presented in Figure 10). 
The staining confirmed that indeed IL-8 and MMP-3 expression are decreased in vivo in 
A375SM cells in which NFAT1 was silenced and MMP-3 and IL-8 expression were 
increased after overexpressing NFAT1 in SB2 cells (Figure 23).  
To verify the angiogeneic role of IL-8, further immunohistochemistry staining was 
performed on both A375SM and SB2 xenograft tumors with anti-CD31, a widely used 
endothelial marker, detecting blood vessels (angiogenesis). A375SM, NFAT1 NT shRNA 
melanoma cells present a high number of blood vessels when compared to NFAT1 shRNA.  
The overexpression of NFAT1 in SB2 cells shows similar phenotype as the highly metastatic 
line A375SM, and it is clearly noticeable that the number of blood vessels is higher after 
NFAT1 overexpression compared to the empty vector SB2-EV (Figure 23).   Apoptosis was 
also analyzed in the tumor sections from our xenograft model using the TUNEL assay.  The 
number of positively stained (dead) tumor cells was significantly increased in NFAT1 
silenced A375SM tumors.  The overexpression of NFAT1 in SB2 cells reduced the number 
of apoptotic cells (Figure 23).   
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TCGA Analysis for the Expression of IL-8 and MMP-3 and Survival 
To further validate the relevance of our downstream target genes in the clinics, we mined the 
TCGA data to investigate if there is a correlation between the expression levels of IL-8 and 
MMP-3 to the survival of patients. The analysis was based on 45 patients that expressed IL-8 
or MMP-3. The results demonstrated that patients with higher expressions of these genes had 
a significantly worst overall survival (p<0.05) than patients with low expression of these 
proteins (Figure 24).  
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Figure 23: Immunohistochemistry of Tumor Samples after Silencing or Overexpressing NFAT1 
in Melanoma Cells 
A375SM melanoma cells with NT /NFAT1 shRNA and SB2 cells with Empty vector/NFAT1 OE 
were injected subcutaneously in nude mice.  NFAT1 remains silenced or Overexpressed in the 
xenograft tumors (upper panel). NFAT1 downstream targets are demonstrating up- and down-
regulation as expected (second and third panel). A representative image of the number of CD31 
positive endothelial cells is shown from A375SM and SB2 xenograft tumors (fifth panel).  Silencing 
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NFAT1 reduces the number of CD31 stained blood vessels within the tumor, while overexpression of 
NFAT1 increases the number of blood vessels. Silencing of NFAT1 increases the number of 
apoptotic TUNEL positive cells within the subcutaneous tumor. Overexpression of NFAT1 in SB2 
cells reduces the number of apoptotic cells in the xenograft model.   
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 A.                                                                                  B. 
 
Figure 24: Expression of IL-8 and MMP-3 Correlates with Survival in Patients (based on 45 
patients from TCGA data)  
Analysis based on TCGA data demonstrating a correlation between survival of patients to levels of 
the proteins IL-8 and MMP-3 in their tumors. (A) Patients with higher IL-8 expression showed a 
lower overall survival (in red) compared with patients have low IL-8 expression (in blue) (B) Patients 
with higher MMP-3 expression showed a lower overall survival (in red) compared with patients that 
have low MMP-3 expression (in blue)    
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Summary Specific Aim 2 
In this aim we identified two novel downstream target genes that are regulated by 
NFAT1 and contribute to melanoma progression.  We established that there is a positive 
correlation between NFAT1 expression with IL-8 and MMP-3 protein expression. We first 
demonstrated that IL-8 is positively regulated at both the transcriptional level and protein 
levels by NFAT1. Silencing of NFAT1 in A375SM and WM902B metastatic cell lines 
resulted in downregulation of IL-8 mRNA and secreted protein levels.  Rescue of NFAT1 in 
those two cell lines also rescued the IL-8 expression at both mRNA and protein levels, which 
emphasizes that IL-8 is directly regulated by NFAT1 expression and not due to an off target 
effect of the transduction.  Moreover, when overexpressing NFAT1 in the low metastatic cell 
line SB2, IL-8 mRNA and secreted protein levels were increased. Furthermore, we 
demonstrated that NFAT1 enhances the promoter activity of IL-8 by utilizing ChIP assay. 
Mutation on the NFAT1 binding site on IL-8 promoter resulted in a significant reduction in 
luciferase activity, indicating a direct binding of NFAT1 to the IL-8 promoter.  At last we 
demonstrated using immunohistochemistry staining, that the regulation of IL-8 and MMP-3 
is also maintained in vivo in the tumor tissue from the xenograft model.  
The second novel target that is regulated by NFAT1 is MMP-3.  Little is known about 
the contribution of MMP-3 in melanoma. A possible role of MMP-3 in the progression and 
metastasis was previously suggested as MMP-3 protein levels were reported to be expressed 
in highly metastatic melanoma cell lines [155, 156], however the role of MMP-3 in 
melanoma progression was not elucidated.  In our study, we validated that indeed the cell 
lines that are used in our lab also have a similar expression profile when looking at MMP-3. 
The more metastatic the cell line is, the higher the MMP-3 expression level it has.  In this 
  
101 
 
study we found that silencing NFAT1 in A375SM and WM902B metastatic melanoma cell 
lines reduced MMP-3 mRNA and protein expression levels. In SB2 cells, overexpression of 
NFAT1 increased the expression of MMP-3 at both the transcriptional and protein levels. We 
further demonstrated that NFAT1 enhances the activity of the MMP-3 promoter.  MMP-3 
promoter has two NFAT1 binding sites and mutation analysis of the promoter showed that 
both binding sites has the same effect on the promoter activity (no significant difference was 
observed) and dual mutation had no additive effect. Silencing NFAT1 or mutation in the 
binding site reduced the luciferase activity of the MMP-3 promoter further establishing the 
role of NFAT1 in the transcriptional regulation of MMP-3. Finally we aimed to elucidate the 
role of MMP-3 in melanoma tumor growth and experimental metastasis. We silenced MMP-
3 expression in a metastatic melanoma cell line (A375SM) and overexpressed MMP-3 in a 
low metastatic cell line (SB2). These cell lines were then utilized for in-vivo studies, where 
they were injected subcutaneously and intravenously to investigate the effect of MMP-3 on 
melanoma tumor growth and metastasis. Our results demonstrate that higher expression of 
MMP-3 in the cells promoted tumor growth and metastasis, which emphasizes the 
importance of MMP-3 to the metastatic phenotype.   
To validate the clinical relevance of our results, we mine the TCGA data and found a 
correlation between the expression levels of IL-8 and MMP-3 to the overall survival of 
patients. Patients with lower levels of IL-8 and MMP-3 show a significantly better survival 
than patients with high expression of the proteins. 
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CHAPTER 5: Discussion, Significance and Future Directions 
 
The role of NFAT1 in the immune response as a T cell activator is very well established. Its 
role in cancer and more so in melanoma is less documented. During this study we revealed 
several novel findings, which further elucidate the role of NFAT1 in melanoma progression. 
We demonstrated that NFAT1 expression positively correlated with the metastatic melanoma 
phenotype in both patient specimens as well as in a panel of cell lines with different 
metastatic potential. In patient specimens, we demonstrated that NFAT1 expression is 
significantly higher in metastatic lesions compared to patients with primary tumors. In cell 
lines, NFAT1 expression increased with the metastatic potential of the cells. To further 
establish the contribution of NFAT1 in melanoma metastasis, we silenced NFAT1 expression 
by lentiviral shRNA in two metastatic melanoma cell lines A375SM and WM902B. We 
found that silencing NFAT1in both cell lines significantly reduced their invasive potential in 
vitro. Overexpression of NFAT1 in the low metastatic melanoma cell line, SB2 significantly 
increased their invasive potential in vitro. In vivo, we demonstrated that silencing of NFAT1 
reduced the tumor growth and metastatic potential of A375SM melanoma cells while 
overexpression of NFAT1 in the low metastatic SB2 cells increased their in vivo metastatic 
properties. To further elucidate the mechanism of action of NFAT1 in melanoma progression 
we subjected the metastatic melanoma cell line A375SM NFAT1-silenced cells to a cDNA 
microarray analysis. We found that NFAT1 positively regulates the expression of IL-8 and 
MMP-3 at the transcriptional level. Chromatin immunoprecipitation assays as well as 
promoter analysis demonstrated that NFAT1 binds to the promoter of IL-8 and MMP-3 and 
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promotes their transcription. Rescue of NFAT1 expression in NFAT1-silenced cells restored 
the protein expression of both IL-8 and MMP-3.  This confirms that our results are not an 
off-target effect of the sh-NFAT1 used in our studies.  
The role of IL-8 in melanoma progression and metastasis has been previously established in 
our laboratory. We therefore decided to concentrate our further studies on elucidating the role 
of MMP-3 in promoting the metastatic melanoma phenotype. In cell lines we demonstrated 
that secreted MMP-3 levels increased with the metastatic potential of the cells. To further 
elucidate the role of MMP-3 in melanoma progression, we stably silenced MMP-3 
expression using letiviral shRNA in the highly metastatic A375SM cells and overexpressed 
MMP-3 in the low metastatic SB2 cells.  These cells were injected into nude mice, both 
subcutaneously and intravenously, to study the role of MMP-3 in tumor growth and 
metastasis. In vivo, we demonstrated that silencing of MMP-3 reduced tumor growth and the 
metastatic potential of A375SM melanoma cells, while overexpression of MMP-3 in the low 
metastatic SB2 significantly increased their tumor growth and metastatic potential. Mining 
the TCGA data, we demonstrated that patients with low expression of IL-8 or MMP-3 have 
significantly better survival rate when compared to patients with high expression of these 
proteins. 
Taken together my work assigns a previously undescribed role for NFAT1 in regulating the 
melanoma metastatic phenotype. 
The main cause of mortality in the majority of melanoma patients is due to distal 
metastases. Regardless of the latest advances in the field, such as BRAF and 
immunocheckpoint modalities, malignant melanoma still presents a major clinical challenge. 
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During melanoma progression, there is a signature of genetic alterations, but to better 
promote the field it is critical to understand the regulation and mechanisms associated with 
metastasis. Therefore, recognizing the events, and genes involved that lead to melanoma 
metastasis is essential for identifying novel therapeutic molecular targets that will 
successfully cure this disease.  
Earlier reports have described the correlation between NFAT1 and melanoma. One 
such published work had demonstrated that the absence of NFAT1 expression in the 
microenvironment caused a significant difference in the ability of the B16F10 melanoma cell 
line to grow [116]. NFAT1 deficient mice presented less experimental lung metastasis 
colonization after B16F10 melanoma cell injections when compared to the WT mice [116]. 
Another related publication presentd NFAT1 as a potential therapeutic target in melanoma, 
since NFAT1 was found to promote proliferation and inhibits melanoma cell apoptosis [117].  
In addition, NFAT1 was found to be an activating transcription factor for the MDM2 
oncogene in response to DNA damage signals [118].  NFAT1 also supports tumor induced 
anergy of CD4
+
  T cells [119] and regulates a set of genes that are responsible for helper T-
cell (CD8
+
) anergy [120]. Data from a recent publication has demonstrated that NFAT1 
increased CTLA-4 promoter activity in CD4
+
 T cells compared to CD8
+
 T cells. The 
expression of CTLA-4 mediated by NFAT1 in CD4
+ 
can potentially be important for anti 
CTLA-4 therapy [121]. Our laboratory has previously demonstrated that Gal-3 regulates 
autotaxin through NFAT1, and high levels of Gal-3 supports melanoma growth and 
metastasis [122]. Taken together, these data indicate that NFAT1 regulates multiple genes 
during melanoma progression. However, the majority of the downstream genes have yet to 
be identified.  The present study showed that indeed NFAT1 positively correlates with the 
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metastatic potential of melanoma cell lines although the mechanism by which NFAT1 
contributes to melanoma progression remains unknown.  In the effort to identify downstream 
target genes regulated by NFAT1, NFAT1 shRNA was used to silence NFAT1 in A375SM 
cells and a CDNA microarray was performed.  We narrowed our study on two downstream 
target genes: IL-8 and MMP-3. NFAT1 was also overexpressed in the low metastatic cell line 
SB2 and both manipulated cell lines (A375SM and SB2) were injected into nude mice both 
subcutaneously (for tumor growth) and intravenously (for experimental lung metastasis) to 
clarify the role of NFAT1 in tumor growth and metastasis. Results from the in vivo 
experiment revealed that overexpressing NFAT1 in the low metastatic cells increased tumor 
growth and metastasis while silencing NFAT1 significantly reduced tumor growth and 
metastasis. Our data validate the assertion that NFAT1 has an active role in melanoma 
progression and metastasis formation. Moreover, upon mining available TCGA data we 
found that NFAT1 is expressed more in metastatic lesions compared to specimens taken from 
benign nevi (Figure 5) so it is consequently clinically relevant to consider NFAT1 and its 
downstream regulated genes, IL-8 and MMP-3, as possible targets to melanoma therapy. 
Imunohistochemistry performed on tumors from the in vivo study demonstrated that in the 
absence of NFAT1, less blood vessels formation and increased apoptosis were observed. 
Imunohistochemistry staining also demonstrated that the correlation between NFAT1 and its 
downstream genes is conserved in vivo. Silencing NFAT1 reduced IL-8 and MMP-3 
expression in the tumor tissue suggesting that its role in regulating crucial downstream 
targets which are necessary for dimelanoma progression. Thus, the NFAT1 transcription 
factor may be an important factor to promote melanoma progression.  
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The chemokine IL-8 is one of the downstream targets identified as being regulated by 
NFAT1 and its expression is shown to be positively correlated with melanoma progression 
[134-136]. Overexpression of IL-8 in melanoma cells up-regulates the expression and 
activity of the matrix metalloproteinase MMP-2, which contributes to a more invasive 
phenotype [137].  Targeting IL-8 could be therapeutically beneficial for melanoma patients, 
due to the pro-tumorigenic and survival dependent effects of IL-8 in cancer.  Using a fully 
human antibody against IL-8 (ABX-1L8) we demonstrated its effect on melanoma growth 
and metastasis. ABX-IL8 significantly reduced tumor growth and experimental lung 
metastasis of A375SM and TXM-13 melanoma cells in vivo mostly by inhibiting 
angiogenesis [141]. IL-8 has been shown to promote the growth, invasiveness, motility, 
angiogenesis, and metastatic potential of melanoma cells [137, 141-143]. Interestingly, 
targeting IL-8 reduced MMP-2 expression, and incubating melanoma cells with ABX-IL-8 
reduced the invasive potential of melanoma cells through Matrigel coated membranes.  
Decreased CD31 staining in vivo and HUVEC tube formation in vitro was also observed 
[141]. In a new ongoing study in the lab, a siRNA delivery approach is being utilized to 
silence IL-8 to reduce melanoma growth and metastasis in vivo.   
The second downstream target, MMP-3, is less investigated in melanoma. MMP-3 
was investigated as a potential serum marker and the levels of MMP-3 in the serum were 
evaluated between healthy patients and malignant melanoma patients but no significant 
differences observed [146, 147].  Another in vivo study reported that Angpt2, MMP-3 and 
MMP-10 are all upregulated in the lung by a mice bearing the B16F10 tumors [151]. The 
lung microenvironment is therefore presenting the pre-metastatic niche that resulted through 
the influence of the primary tumor. Recently, SOX2 (an embryonic stem cell transcription 
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factor) was found to be expressed in human melanoma cells [152, 153]. It was also shown 
that after silencing SOX2 in melanoma cells, the expression of MMP-3 was reduced by 
almost 90% [154]. From the association between SOX2 and MMP-3, it was suggested that 
MMP-3 is regulated by SOX2 and that their co-expression may be used as a functional 
biomarker for invasive melanoma cells [154].   Data from our current study showed that 
NFAT1 binds to the MMP-3 promoter and regulates its expression. Also, we validated that 
there is a direct correlation between MMP-3 protein levels with the metastatic potential of 
melanoma cell lines.  To further clarify the role of MMP-3 in melanoma progression we 
utilized A375SM cells with MMP-3 shRNA and SB2 cells with MMP-3 overexpression. 
Both manipulated cell lines were injected subcutaneously and intravenously to study the role 
of MMP-3 in tumor growth and metastasis.  In SB2 cells, higher MMP-3 expression resulted 
in an increase of tumor growth and experimental lung metastasis.  In contrast, silenced 
MMP-3 in A375SM cells resulted with a significant reduction in both the number of 
metastases and tumor size (Figure 22).  Evidence from this investigation led to the 
conclusion that NFAT1 is a regulator of a number of important genes that support melanoma 
growth and metastasis including IL-8 and MMP-3.  Hence, NFAT1 expression is essential 
for melanoma progression.  Our findings identify a previously unknown mechanism by 
which NFAT1 promotes melanoma growth and metastasis through its positive regulation of 
IL-8 and MMP-3 protein expression.  
Therapies for the treatment of metastatic melanoma that target NFAT1, IL-8 or 
MMP-3 have not yet to been studied.  Throughout our study, we identify a novel mechanism 
for melanoma progression in which NFAT1 regulates IL-8 and MMP-3 and promotes the 
malignant phenotype.  Targeting NFAT1 could be a potential therapeutic tool.  Therapy 
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directed at NFAT1 is clinically feasible as shown with cyclosporine A to inhibit T-cell 
mediated organ transplant rejection [157].  However, in melanoma, immunotherapy and 
immunesurveillance promoted by T-cells are considered methods for melanoma treatment.  
Therefore, systemic therapy directed towards NFAT1 in melanoma could be counterintuitive 
by reducing T-cell activity.  Yet, not all T-cells have anti-tumor function.  Regulatory T-cells 
(Treg) can reduce the immune response towards tumors, and it’s been shown that NFAT1 
enhances Treg activity as well (Reviewed in [158, 159]).  The multiple roles of NFAT1 
within the tumor microenvironment create a “double edged sword” in regards to its 
therapeutic potential.  Therefore, directing therapy towards the downstream targets IL-8 and 
MMP-3 instead of NFAT1 could be a better choice.   
 
The impact of these findings can translate to the clinic by improving treatment 
options for metastatic melanoma.  Results suggest that targeting IL-8, MMP-3, or both as 
therapy for melanoma is possible either alone or in combination with immunotherapy or 
chemotherapy.  Data from the survival curves (Kaplan Meier) reveal a potential connection 
between IL-8 and MMP-3 expression and patient survival highlighting the likely success of 
utilizing these two targets for therapeutic purposes.  Treatment options focused on targeting 
IL-8 and MMP-3 can be taken towards several directions including finding the connection 
between IL-8 expression and BRAF resistance in melanoma cells. Further analysis may 
examine the change in IL-8 levels due to resistance and whether the use of IL-8 inhibiting 
antibody will regress cellular resistance to BRAF inhibitors.   
Based on our results, it can be established that after silencing NFAT1, reduction in 
tumor size can be partially due to a reduction in angiogenesis resulted from a decrease in IL-
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8 expression.  These data suggest that NFAT1 may promote melanoma by functioning as a 
regulator of downstream targets that in turn can be affecting interactions with the 
microenvironment.  
Our previous data present a novel mechanism in which autotaxin is regulated by Gal-
3 through NFAT1 [122]. Along with our current data, this implicates that NFAT1 plays 
major roles in modulating the tumor microenvironment to support melanoma growth and 
metastasis (Figure 25). Taken together, our findings establish a novel mechanism by which 
NFAT1 contributes to melanoma growth and metastasis through the regulation of IL-8 and 
MMP-3. This is the first report of a mechanistic role of NFAT1 in melanoma progression and 
serves as foundation for future studies in this area.  
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Figure 25: Proposed Mechanism for the Role of NFAT1 in Melanoma Progression  
Increased of NFAT1 expression in metastatic melanoma cells promotes its activation as a 
transcription factor in the nucleus. Therefore, promotes its downstream target genes. IL-8 and MMP-3 
are supporting angiogenesis, invasion and cell survival, and result increase in tumor growth and 
metastasis. 
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